[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 336
1. Sonar S, D'Souza SE, Mishra KP: A simple one-step protocol for preparing small-sized doxorubicin-loaded liposomes. J Environ Pathol Toxicol Oncol; 2008;27(3):181-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Parameters such as stock concentration of phospholipid, injection ratio, lipid composition, and drug-to-phospholipid ratio affected the resultant liposome size and magnitude of doxorubicin encapsulation.
  • A lipid stock concentration (50 mM) and injection ratio (1:10) resulted in 96.0 +/- 2.92% encapsulation efficiency of doxorubicin (drug-to-lipid mole ratio: 0.192) and mean diameter of 135 +/- 2.32 nm for SCOL-2 formulation (DSPC/ cholesterol /oleic acid: 2/2/1; molar ratios).
  • These findings offer promise for scale-up and development on a large-scale production of doxorubicin-loaded liposomes for effective cancer therapy.
  • [MeSH-minor] Drug Carriers. Drug Delivery Systems. Liposomes

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18652565.001).
  • [ISSN] 0731-8898
  • [Journal-full-title] Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer
  • [ISO-abbreviation] J. Environ. Pathol. Toxicol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Drug Carriers; 0 / Liposomes; 80168379AG / Doxorubicin
  •  go-up   go-down


2. Aida K, Monia K, Ahlem S, Dominique HT, Becima F, Sylvie F, Ridha KM: Agminated Spitz nevi arising on a nevus spilus after chemotherapy. Pediatr Dermatol; 2010 Jul-Aug;27(4):411-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Agminated Spitz nevi arising on a nevus spilus after chemotherapy.
  • Agminated Spitz nevus arising on a background of nevus spilus (NS) is a rare condition.
  • We report here a further case in a child that is original because it is induced by chemotherapy.
  • A 3-year-old boy presented 3 months after the onset of a chemotherapy for a vesico-prostatic rhabdomyosarcoma, multiple pigmented papulo-nodules located on the face, neck, chest wall, and the higher back.
  • These lesions have arose on a pre-existent large congenital histologically confirmed nevus spilus extending along the face, neck, the left shoulder and the left chest wall.
  • Histological examination of three excised nodules led to the diagnosis of Spitz nevus.
  • Our patient may have a high risk for melanoma since he has many criteria predisposing to this risk.
  • Some of these criteria are related to NS but we should also take into account the chemotherapy induction and the high number of Spitz nevi.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Nevus, Epithelioid and Spindle Cell / chemically induced. Prostatic Neoplasms / drug therapy. Rhabdomyosarcoma / drug therapy. Skin Neoplasms / chemically induced. Urinary Bladder Neoplasms / drug therapy


3. Cole LA, Khanlian SA: Inappropriate management of women with persistent low hCG results. J Reprod Med; 2004 Jun;49(6):423-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Quiescent gestational trophoblastic disease (GTD) was identified in 121 cases by the absence of invasive trophoblast antigen and nonresponse to chemotherapy (64 cases with a history of hydatidiform mole or gestational trophoblastic neoplasia (GTN) and 57 cases following antecedent pregnancy).
  • Another 61 Reference Service cases hadfalse positive hCG, and we observed 7 cases with low levels of hCG of pituitary origin (hCG subsequently suppressed by estrogen-progesterone medication).
  • Most disturbing is that the majority of these cases (68%) received needless therapy for assumed GTN/choriocarcinoma/placental site trophoblastic tumor before consultation with the Reference Service.
  • One hundred twenty-eight of the 189 patients (77 of 121 with quiescent GTD, 48 of 61 withfalse positive hCG and 3 of 7 with pituitary hCG) underwent therapy ranging from single-agent chemotherapy (117 cases), to EMA-CO combination chemotherapy (etoposide, methotrexate, actinomycin D alternating with cyclophosphamide and vincristine) (16 cases), to hysterectomy and/or bilateral salpingo-oophorectomy (31 cases).
  • False positive hCG and pituitary hCG would obviously not respond to these treatments, and no treated cases of quiescent GTD responded to chemotherapy orfully responded to hysterectomy.
  • The continued needless treatment of patients with quiescent GTD, even after multiple publications, is entirely avoidable.
  • [MeSH-major] Chorionic Gonadotropin / analysis. Diagnostic Errors. Gestational Trophoblastic Disease / diagnosis. Gestational Trophoblastic Disease / surgery. Hydatidiform Mole / diagnosis. Hydatidiform Mole / surgery
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. False Positive Reactions. Female. Humans. Hysterectomy. Ovariectomy. Pregnancy. Reference Values. Retrospective Studies

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15283048.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / HD35654
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin
  •  go-up   go-down


Advertisement
4. Ulamec M, Soldo-Belić A, Vucić M, Buljan M, Kruslin B, Tomas D: Melanoma with second myxoid stromal changes after personally applied prolonged phototherapy. Am J Dermatopathol; 2008 Apr;30(2):185-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanoma with second myxoid stromal changes after personally applied prolonged phototherapy.
  • Most malignant melanomas are easily diagnosed; however, melanoma is also one of the lesions most frequently reported to mimic other tumors.
  • A case is presented of primary cutaneous melanoma with abundant myxoid matrix in a patient who underwent prolonged phototherapy.
  • Three years before, after getting sunburns, the patient noticed changes of a congenital nevus located in the area of sunburns.
  • Chemotherapy and immunotherapy were administered as suggested by an oncologist.
  • Although some authors believe that myxoid changes do not seem to alter the behavior of melanoma, it remains an important differential diagnosis issue.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Lymph Nodes / pathology. Melanoma / secondary. Phototherapy / methods. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy, Needle. Follow-Up Studies. Humans. Immunohistochemistry. Lymphatic Metastasis. Male. Neoplasm Staging. Risk Assessment. Time Factors

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18360128.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Karbowniczek M, Spittle CS, Morrison T, Wu H, Henske EP: mTOR is activated in the majority of malignant melanomas. J Invest Dermatol; 2008 Apr;128(4):980-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective of this study was to determine whether activation of the kinase mammalian target of rapamycin (mTOR) is associated with human melanoma.
  • In contrast, only 3/67 benign nevi (4%) were moderately positive, and none were strongly positive.
  • These data indicate that mTOR activation is very strongly associated with malignant, compared to benign, melanocytic lesions.
  • Next, we tested six melanoma-derived cell lines for evidence of mTOR dysregulation.
  • The proliferation of three melanoma-derived lines was blocked by the mTOR inhibitor rapamycin, indicating that mTOR activation is a growth-promoting factor in melanoma-derived cells. mTOR is directly activated by the small guanosine triphosphatase Ras homolog enriched in brain (Rheb), in a farnesylation-dependent manner.
  • Therefore, to investigate the mechanism of mTOR activation, we used the farnesyl transferase inhibitor FTI-277, which partially blocked the growth of three of the six melanoma cell lines.
  • Together, these data implicate activation of mTOR in the pathogenesis of melanoma, and suggest that Rheb and mTOR may be targets for melanoma therapy.
  • [MeSH-major] Melanoma / enzymology. Melanoma / pathology. Protein Kinases / metabolism. Skin Neoplasms / enzymology. Skin Neoplasms / pathology
  • [MeSH-minor] Cell Line, Tumor. Cell Proliferation / drug effects. DNA Mutational Analysis. Humans. Nevus / enzymology. Nevus / pathology. Phosphorylation. Protein Kinase Inhibitors / pharmacology. Proto-Oncogene Proteins B-raf / genetics. Proto-Oncogene Proteins p21(ras) / genetics. Ribosomal Protein S6 / metabolism. Sirolimus / pharmacology. TOR Serine-Threonine Kinases

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17914450.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK 51052
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Ribosomal Protein S6; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras); W36ZG6FT64 / Sirolimus
  •  go-up   go-down


6. Kerkmeijer L, Wielsma S, Bekkers R, Pyman J, Tan J, Quinn M: Guidelines following hydatidiform mole: a reappraisal. Aust N Z J Obstet Gynaecol; 2006 Apr;46(2):112-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guidelines following hydatidiform mole: a reappraisal.
  • OBJECTIVE: The aim of this study was to determine how often patients with complete hydatidiform mole (CHM) who spontaneously achieve normal human chorionic gonadotrophin (hCG) levels subsequently develop persistent or recurrent gestational trophoblast disease.
  • METHODS: Four hundred and fourteen cases of CHM registered at the Hydatidiform Mole Registry of Victoria were reviewed retrospectively after molar evacuation.
  • Maternal age, gestational age, gravidity and parity were determined for each patient, as well as the need for chemotherapy.
  • RESULTS: Among the 414 patients, 55 (13.3%) required chemotherapy for persistent trophoblastic disease.
  • None of the patients whose hCG levels spontaneously fell to normal subsequently developed persistent molar disease.
  • [MeSH-major] Chorionic Gonadotropin / blood. Hydatidiform Mole / diagnosis. Neoplasm Recurrence, Local / diagnosis. Practice Guidelines as Topic. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Adult. Biomarkers, Tumor / blood. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Hysterectomy / methods. Maternal Age. Monitoring, Physiologic / standards. Parity. Pregnancy. Pregnancy Complications, Neoplastic / diagnosis. Pregnancy Complications, Neoplastic / therapy. Pregnancy Outcome. Registries. Retrospective Studies. Risk Assessment. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Hydatidiform mole.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Aust N Z J Obstet Gynaecol. 2006 Jun;46(3):179. Wiesma, Sabien [corrected to Wielsma, Sabien]
  • (PMID = 16638032.001).
  • [ISSN] 0004-8666
  • [Journal-full-title] The Australian & New Zealand journal of obstetrics & gynaecology
  • [ISO-abbreviation] Aust N Z J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin
  •  go-up   go-down


7. Pautier P, Ghione S, Brailly-Tabard S, Lhommé C, Morice P, Bidart JM: Are serum inhibin concentrations new markers of placental tumours in the course of chemotherapy? Hum Reprod; 2001 Nov;16(11):2434-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are serum inhibin concentrations new markers of placental tumours in the course of chemotherapy?
  • BACKGROUND: The study was conducted to evaluate whether the detection of serum molecular forms of inhibin (A and B) could be useful for the diagnosis, prognosis and follow-up of placental tumours.
  • METHODS: A total of 17 patients with hydatidiform mole (n = 13), invasive mole (n = 1) or choriocarcinoma (n = 3) were studied; serum concentrations of inhibins A and B, human chorionic gonadotrophin (HCG) and its free beta subunit (HCGbeta) were measured before chemotherapy (after mole evacuation for eight patients) and also during the course of chemotherapy (for 10 patients).
  • RESULTS: After evacuation or before chemotherapy for refractory disease, serum inhibin A and B concentrations were found to be increased in 10/17 and 4/17 patients, when HCG and HCGbeta were high in all patients.
  • In 10 patients with a follow-up during treatment, nine had a high concentration of inhibin A which correlated with those of HCG and HCGbeta.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / blood. Choriocarcinoma / blood. Hydatidiform Mole / blood. Inhibins / blood. Uterine Neoplasms / blood

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11679534.001).
  • [ISSN] 0268-1161
  • [Journal-full-title] Human reproduction (Oxford, England)
  • [ISO-abbreviation] Hum. Reprod.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin; 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / inhibin A; 0 / inhibin B; 57285-09-3 / Inhibins
  •  go-up   go-down


8. Bhowmick S, Swanlund DJ, Bischof JC: Supraphysiological thermal injury in Dunning AT-1 prostate tumor cells. J Biomech Eng; 2000 Feb;122(1):51-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To investigate the potential application of thermal therapy in the treatment of prostate cancer, the effects of supraphysiological temperatures (40-70 degrees C) for clinically relevant time periods (approximately 15 minutes) were experimentally studied on attached Dunning AT-1 rat prostate cancer cells using multiple assays.
  • Experimental results from all three assays show a broad trend of increasing injury with an increase in temperature and time of insult.
  • Last, although the clonogenic assay yields the most accurate cell survival data, it is difficult to acquire these data at temperatures > or = 50 degrees C because the thermal transients in the experimental setup are significant as compared to the time scale of the experiment.
  • The activation energy (E) obtained using the Arrhenius model for an injury criterion of 30 percent for all three assays revealed that the mechanism of thermal injury measured is likely different for each of the three assays: clonogenics (526.39 kJ/mole), PI (244.8 kJ/mole), and calcein (81.33 kJ/mole).
  • Moreover, the sensitivity of the rate of injury accumulation (d omega/dt) to temperature was highest for the clonogenic assay, lowest for calcein leakage, and intermediate for PI uptake, indicating the strong influence of E value on d omega/dt.
  • For higher temperatures (> or = 50 degrees C) indicative of thermal therapies, the results of PI uptake can be used as a conservative estimate of cell death (underprediction).
  • These results provide further insights into the mechanisms of thermal injury in single cell systems and may be useful for designing optimal protocols for clinical thermal therapy.
  • [MeSH-major] Cell Membrane Permeability / physiology. Hot Temperature / adverse effects. Hot Temperature / therapeutic use. Hyperthermia, Induced / adverse effects. Hyperthermia, Induced / methods. Models, Biological. Prostatic Neoplasms / pathology. Prostatic Neoplasms / therapy. Tumor Cells, Cultured / physiology
  • [MeSH-minor] Animals. Cell Survival. Colony-Forming Units Assay. Coloring Agents / pharmacokinetics. Fluoresceins / metabolism. Male. Propidium / pharmacokinetics. Rats. Reproducibility of Results. Sensitivity and Specificity. Temperature. Time Factors

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10790830.001).
  • [ISSN] 0148-0731
  • [Journal-full-title] Journal of biomechanical engineering
  • [ISO-abbreviation] J Biomech Eng
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Coloring Agents; 0 / Fluoresceins; 36015-30-2 / Propidium; V0YM2B16TS / fluorexon
  •  go-up   go-down


9. Pongcharoen S, Bulmer JN, Searle RF: No evidence for apoptosis of decidual leucocytes in normal and molar pregnancy: implications for immune privilege. Clin Exp Immunol; 2004 Nov;138(2):330-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No evidence for apoptosis of decidual leucocytes in normal and molar pregnancy: implications for immune privilege.
  • Complete hydatidiform moles are totally paternally derived and represent complete allografts that might be expected to provoke maternal immune rejection.
  • Our previous and other studies have shown expression of Fas by increased numbers of activated decidual CD4(+) T cells in both complete and partial molar pregnancy as well as increased FasL(+) expression by molar trophoblasts compared with trophoblasts in normal pregnancies.
  • As the Fas/FasL system represents a major apoptotic pathway that can play a role in immune privilege, the aim of this study was to investigate whether apoptosis of decidual immune cells, particularly T cells, could be responsible for maternal immune tolerance in molar pregnancy.
  • Using terminal deoxynucleotidyl transferase (TdT)-mediated nick end-labelling (TUNEL), a significant increase in TUNEL(+) cells was demonstrated in decidua associated with partial (P = 0.0052) and complete (P = 0.0096) hydatidiform mole compared with normal early pregnancy.
  • Double immunostaining with anticytokeratin to detect trophoblast and M30 CytoDeath, which detects a neoepitope of cytokeratin 18 revealed after caspase-mediated cleavage, revealed apoptotic extravillous trophoblast cells within decidual tissue.
  • We conclude that there is no evidence that apoptosis of decidual leucocytes plays a role in maintaining maternal tolerance in either normal or molar pregnancy.
  • [MeSH-major] Apoptosis / immunology. Decidua / immunology. Hydatidiform Mole / immunology. Immune Tolerance / immunology. Leukocytes / immunology. Uterine Neoplasms / immunology

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Reprod. 1999 Dec;14 Suppl 2:59-66 [10690801.001]
  • [Cites] Am J Reprod Immunol. 1999 Aug;42(2):88-94 [10476690.001]
  • [Cites] Immunology. 2000 Jul;100(3):289-99 [10929050.001]
  • [Cites] Am J Reprod Immunol. 2001 Feb;45(2):108-15 [11216873.001]
  • [Cites] Placenta. 2001 Jan;22(1):44-8 [11162351.001]
  • [Cites] Biol Reprod. 2001 Mar;64(3):784-9 [11207192.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jan;21(1):41-7 [11781522.001]
  • [Cites] Mol Hum Reprod. 2002 Mar;8(3):255-61 [11870233.001]
  • [Cites] Am J Pathol. 2002 Jul;161(1):105-14 [12107095.001]
  • [Cites] Placenta. 2003 May;24(5):540-8 [12744931.001]
  • [Cites] Am J Reprod Immunol. 2003 Jul;50(1):41-7 [14506927.001]
  • [Cites] Mol Hum Reprod. 2004 Jan;10(1):55-63 [14665707.001]
  • [Cites] Placenta. 2004 Apr;25(4):321-30 [15028424.001]
  • [Cites] Nature. 1977 Aug 18;268(5621):633-4 [561314.001]
  • [Cites] Am J Obstet Gynecol. 1978 Jul 15;131(6):665-71 [686053.001]
  • [Cites] Am J Obstet Gynecol. 1979 Nov 1;135(5):597-600 [92196.001]
  • [Cites] Hum Reprod. 1991 Jul;6(6):791-8 [1757516.001]
  • [Cites] Biol Reprod. 1992 Mar;46(3):328-34 [1352146.001]
  • [Cites] Cell. 1993 Dec 17;75(6):1169-78 [7505205.001]
  • [Cites] J Immunol. 1994 Nov 15;153(10):4427-35 [7525703.001]
  • [Cites] Histochem Cell Biol. 1995 Feb;103(2):157-60 [7634155.001]
  • [Cites] Science. 1995 Oct 27;270(5236):630-3 [7570020.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Aug;81(8):3119-22 [8768884.001]
  • [Cites] J Histochem Cytochem. 1996 Sep;44(9):959-68 [8773561.001]
  • [Cites] J Reprod Immunol. 1996 Feb;30(1):53-66 [8920167.001]
  • [Cites] Nature. 1997 Apr 3;386(6624):517-21 [9087414.001]
  • [Cites] Nat Med. 1997 Jul;3(7):738-43 [9212099.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Sep;82(9):3173-5 [9284765.001]
  • [Cites] Mol Hum Reprod. 1997 Aug;3(8):655-62 [9294848.001]
  • [Cites] Placenta. 1998 May;19(4):269-77 [9639322.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1305-8 [9721089.001]
  • [Cites] Cell. 1998 Aug 21;94(4):491-501 [9727492.001]
  • [Cites] Nat Med. 1998 Sep;4(9):1020-4 [9734394.001]
  • [Cites] Am J Reprod Immunol. 1998 Aug;40(2):89-94 [9764350.001]
  • [Cites] Am J Reprod Immunol. 1998 Sep;40(3):130-5 [9764356.001]
  • [Cites] J Reprod Immunol. 1998 Aug;39(1-2):133-48 [9786458.001]
  • [Cites] Am J Reprod Immunol. 1999 Jan;41(1):41-51 [10097786.001]
  • [Cites] J Immunol Methods. 1999 Apr 22;224(1-2):185-96 [10357218.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Jun;84(6):2188-94 [10372730.001]
  • [Cites] Am J Pathol. 1999 Jul;155(1):293-301 [10393861.001]
  • [Cites] Am J Reprod Immunol. 1999 Jul;42(1):1-13 [10429761.001]
  • [Cites] J Clin Pathol. 1999 Dec;52(12):888-94 [10711251.001]
  • (PMID = 15498045.001).
  • [ISSN] 0009-9104
  • [Journal-full-title] Clinical and experimental immunology
  • [ISO-abbreviation] Clin. Exp. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Enzyme Precursors; 68238-35-7 / Keratins; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
  • [Other-IDs] NLM/ PMC1809221
  •  go-up   go-down


10. Oguz S, Sargin A, Aytan H, Kelekci S, Dumanli H: Doppler study of myometrium in invasive gestational trophoblastic disease. Int J Gynecol Cancer; 2004 Sep-Oct;14(5):972-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Thirty-seven patients, who were enrolled in the study with invasive mole, were assessed with the help of transvaginal color Doppler ultrasound before and after chemotherapy.
  • RESULTS: Thirty patients of 37 were treated with the help of single-agent chemotherapy--methotrexate (mtx).
  • When the depth and the width of the myometrial invasion increase and when there is a low diastolic/systolic ratio, the number of courses and the need for combination of chemotherapy increase.
  • [MeSH-minor] Adolescent. Adult. Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Agents, Alkylating / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dactinomycin / administration & dosage. Diagnosis, Differential. Female. Humans. Methotrexate / therapeutic use. Middle Aged. Neoplasm Invasiveness. Prognosis. Prospective Studies. Sensitivity and Specificity. Vagina / ultrasonography

  • Genetic Alliance. consumer health - Gestational Trophoblastic Disease.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15361211.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 1CC1JFE158 / Dactinomycin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


11. Cohn DE, Herzog TJ: Gestational trophoblastic diseases: new standards for therapy. Curr Opin Oncol; 2000 Sep;12(5):492-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gestational trophoblastic diseases: new standards for therapy.
  • These diseases vary from partial hydatidiform mole, which rarely metastasizes and infrequently requires treatment with chemotherapy, to choriocarcinoma, for which multi-agent chemotherapy is the standard treatment.
  • This review highlights these recent advancements in the epidemiology, genetics, diagnosis, and treatment of gestational trophoblastic disease.
  • [MeSH-major] Trophoblastic Neoplasms / therapy
  • [MeSH-minor] Female. Follow-Up Studies. Humans. Neoplasm Staging. Pregnancy. Prognosis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10975558.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 20
  •  go-up   go-down


12. Wang CC, Huang YL, Ren CT, Lin CW, Hung JT, Yu JC, Yu AL, Wu CY, Wong CH: Glycan microarray of Globo H and related structures for quantitative analysis of breast cancer. Proc Natl Acad Sci U S A; 2008 Aug 19;105(33):11661-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Understanding their roles in cancer progression will lead to the development of new therapeutics and high-sensitivity diagnostics for cancers.
  • Compared with the traditional ELISA method, this array method required only atto-mole amounts of materials and is more effective and more sensitive (5 orders of magnitude).
  • The glycan microarray thus provides a new platform for use to monitor the immune response to carbohydrate epitopes after vaccine therapy or during the course of cancer progression.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chem Biol. 2002 Apr;9(4):443-54 [11983333.001]
  • [Cites] Lupus. 2006;15(7):442-50 [16898180.001]
  • [Cites] Angew Chem Int Ed Engl. 2002 Sep 2;41(17):3180-2 [12207382.001]
  • [Cites] Chembiochem. 2002 Sep 2;3(9):819-22 [12210981.001]
  • [Cites] Nat Biotechnol. 2002 Oct;20(10):1011-7 [12219077.001]
  • [Cites] J Am Chem Soc. 2002 Dec 4;124(48):14397-402 [12452714.001]
  • [Cites] Curr Opin Struct Biol. 2003 Oct;13(5):637-45 [14568620.001]
  • [Cites] Chembiochem. 2004 Mar 5;5(3):379-82 [14997532.001]
  • [Cites] Lab Chip. 2003 Nov;3(4):260-5 [15007456.001]
  • [Cites] Angew Chem Int Ed Engl. 2004 Mar 12;43(12):1591-4 [15022242.001]
  • [Cites] Chem Biol. 2004 Jun;11(6):875-81 [15217620.001]
  • [Cites] Chemistry. 2004 Jul 5;10(13):3308-14 [15224340.001]
  • [Cites] J Am Chem Soc. 2004 Jul 21;126(28):8640-1 [15250702.001]
  • [Cites] Cancer Res. 1983 Mar;43(3):1295-300 [6337705.001]
  • [Cites] Cancer Res. 1983 Mar;43(3):1301-5 [6186373.001]
  • [Cites] J Biol Chem. 1983 Jul 25;258(14):8934-42 [6863318.001]
  • [Cites] J Biol Chem. 1984 Dec 10;259(23):14773-7 [6501317.001]
  • [Cites] Semin Cancer Biol. 1995 Dec;6(6):357-66 [8938274.001]
  • [Cites] Chem Biol. 1997 Feb;4(2):97-104 [9190292.001]
  • [Cites] Int J Cancer. 1997 Sep 26;73(1):42-9 [9334808.001]
  • [Cites] Clin Cancer Res. 1998 Feb;4(2):295-302 [9516914.001]
  • [Cites] Glycoconj J. 1998 Mar;15(3):243-9 [9579801.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17033-8 [15563589.001]
  • [Cites] J Biol Chem. 2005 Feb 11;280(6):4307-12 [15563466.001]
  • [Cites] Chemistry. 2005 May 6;11(10):2894-901 [15635679.001]
  • [Cites] Nat Rev Drug Discov. 2005 Jun;4(6):477-88 [15931257.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13372-7 [16174734.001]
  • [Cites] J Mol Biol. 2006 Feb 3;355(5):1143-55 [16343533.001]
  • [Cites] Nature. 2006 Jan 12;439(7073):168-74 [16273093.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 3;103(1):15-20 [16373501.001]
  • [Cites] Int J Cancer. 2006 Jun 15;118(12):3161-6 [16395706.001]
  • [Cites] J Am Chem Soc. 2006 Oct 25;128(42):13668-9 [17044677.001]
  • [Cites] Curr Pharm Des. 2007;13(2):173-83 [17269926.001]
  • [Cites] Glycobiology. 2007 Aug;17(8):17C-23C [17483136.001]
  • [Cites] J Am Chem Soc. 2007 Sep 12;129(36):11177-84 [17705486.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11667-72 [18685093.001]
  • [Cites] Nat Rev Microbiol. 2006 Nov;4(11):857-64 [17013397.001]
  • [Cites] Nat Biotechnol. 2002 Mar;20(3):275-81 [11875429.001]
  • [Cites] Nat Chem Biol. 2006 May;2(5):238-48 [16619023.001]
  • [Cites] Science. 2006 Apr 21;312(5772):404-10 [16543414.001]
  • [Cites] Angew Chem Int Ed Engl. 2006 Apr 21;45(17):2753-7 [16548041.001]
  • [Cites] Angew Chem Int Ed Engl. 2006 May 26;45(22):3607-10 [16639753.001]
  • [Cites] Chem Biol. 2002 Jun;9(6):713-20 [12079783.001]
  • (PMID = 18689688.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Globo-H; 0 / Polysaccharides
  • [Other-IDs] NLM/ PMC2575271
  •  go-up   go-down


13. Dhall G, Ginsburg HB, Bodenstein L, Fefferman NR, Greco MA, Chang MW, Gardner S: Thymoma in Children: Report of Two Cases and Review of Literature. J Pediatr Hematol Oncol; 2004 Oct;26(10):681-685
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Surgery is the treatment of choice for stage I and stage II tumors.
  • Chemotherapy is reserved for patients with refractory or metastatic disease.
  • However, radiation therapy is not an attractive option for children due to its side-effects on developing organs.
  • One of the patients also has nevus sebaceous.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27811613.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Zhang Y, Xiang Y, Ren T, Wan XR, Yang XY: [Study on the indication of surgical resection of pulmonary metastasis of malignant trophoblastic tumor]. Zhonghua Fu Chan Ke Za Zhi; 2005 Feb;40(2):83-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ninety-five cases including those that underwent lung lobectomy and cases with normal level of serum human chorionic gonadotropin-beta subunit (beta-hCG, < 2 IU/L) and residual pulmonary nodules after chemotherapy were selected and studied.
  • RESULTS: Lung lobectomies were performed on six cases of invasive mole with lung metastasis and the pathological results were all necrotic nodules;another 35 cases of invasive mole with normal level of serum beta-hCG but residual pulmonary nodules after chemotherapy have been followed up for 6 months to 11 years and all were stable of diseases (SD).
  • Among them, there were 17 cases whose pathological results were hemorrhage and necrotic tissue without trophoblastic cells (negative pathological results), while trophoblastic cells could still be detected in 12 cases of resected lung specimens (positive pathological results).
  • Twenty-five cases of choriocarcinoma with normal serum beta-hCG but residual pulmonary nodules after chemotherapy were followed up, five cases had progress of disease (PD) and 20 were SD.
  • CONCLUSIONS: For invasive mole, lung metastasis can be successfully treated by chemotherapy alone.
  • Patients with residual pulmonary nodules but normal serum beta-hCG after chemotherapy can be followed up and spared lung lobectomy.
  • Progression of disease after multiple chemotherapy courses should be treated with lung lobectomy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chorionic Gonadotropin, beta Subunit, Human / blood. Lung Neoplasms / surgery. Trophoblastic Neoplasms / surgery. Uterine Neoplasms / surgery
  • [MeSH-minor] Adult. Choriocarcinoma / drug therapy. Choriocarcinoma / pathology. Choriocarcinoma / surgery. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Hydatidiform Mole, Invasive / drug therapy. Hydatidiform Mole, Invasive / pathology. Hydatidiform Mole, Invasive / surgery. Lung / radiography. Methotrexate / administration & dosage. Pneumonectomy. Pregnancy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15840284.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human; 1CC1JFE158 / Dactinomycin; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


15. Noal S, Joly F, Leblanc E: [Management of gestational trophoblastic disease]. Gynecol Obstet Fertil; 2010 Mar;38(3):193-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gestational trophoblastic diseases comprise of hydatiform mole, invasive mole, choriocarcinoma and placental site trophoblastic tumor.
  • Hydatiform moles have to be treated by suction rather than curettage.
  • Chemorefractarory patients keep deep prognosis with 5 years survival rate of 43%, which allow development of new therapy in this indication.
  • [MeSH-major] Gestational Trophoblastic Disease / therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Choriocarcinoma / diagnosis. Choriocarcinoma / epidemiology. Choriocarcinoma / therapy. Chorionic Gonadotropin / blood. Drug Resistance, Neoplasm. Female. Humans. Hydatidiform Mole / diagnosis. Hydatidiform Mole / epidemiology. Hydatidiform Mole / therapy. Pregnancy. Prognosis. Risk Factors. Suction. Trophoblastic Tumor, Placental Site / diagnosis. Trophoblastic Tumor, Placental Site / epidemiology. Trophoblastic Tumor, Placental Site / therapy. Uterine Neoplasms / diagnosis. Uterine Neoplasms / epidemiology. Uterine Neoplasms / therapy

  • Genetic Alliance. consumer health - Gestational Trophoblastic Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20189434.001).
  • [ISSN] 1769-6682
  • [Journal-full-title] Gynécologie, obstétrique & fertilité
  • [ISO-abbreviation] Gynecol Obstet Fertil
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Chorionic Gonadotropin
  • [Number-of-references] 42
  •  go-up   go-down


16. Yoshimura K, Sato K, Aiba-Kojima E, Matsumoto D, Machino C, Nagase T, Gonda K, Koshima I: Repeated treatment protocols for melasma and acquired dermal melanocytosis. Dermatol Surg; 2006 Mar;32(3):365-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Repeated treatment protocols for melasma and acquired dermal melanocytosis.
  • BACKGROUND AND OBJECTIVE: Melasma and acquired dermal melanocytosis (ADM; acquired bilateral nevus of Ota-like macules) are both seen most commonly symmetrically on the face of women with darker skin and are also known as difficult conditions to treat.
  • METHODS: Our topical bleaching protocol with 0.1 to 0.4% tretinoin gel and 5% hydroquinone was performed repeatedly (1-3 times) for melasma (n=163), and a combination treatment with topical bleaching and Q-switched ruby (QSR) laser was performed repeatedly (1-3 times) for ADM (n=62).
  • CONCLUSION: The repeated treatment protocol for melasma and ADM showed successful clinical results compared with conventional ones, and they may be applied to other pigment conditions.
  • It may be better that epidermal and dermal pigmentations are treated separately, especially in dark-skinned people who are more likely to suffer postinflammatory hyperpigmentation after inflammation-inducing therapies.
  • [MeSH-major] Facial Neoplasms / therapy. Keratolytic Agents / administration & dosage. Low-Level Light Therapy. Melanosis / therapy. Nevus, Pigmented / therapy. Skin Neoplasms / therapy. Tretinoin / administration & dosage
  • [MeSH-minor] Adult. Antioxidants / administration & dosage. Asian Continental Ancestry Group. Combined Modality Therapy. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Hydroquinones / administration & dosage. Male. Middle Aged. Retreatment. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. HYDROQUINONE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16640680.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Hydroquinones; 0 / Keratolytic Agents; 123-31-9 / hydroquinone; 5688UTC01R / Tretinoin
  •  go-up   go-down


17. Schorge JO, Goldstein DP, Bernstein MR, Berkowitz RS: Recent advances in gestational trophoblastic disease. J Reprod Med; 2000 Sep;45(9):692-700
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent advances have increased our understanding of gestational trophoblastic disease, and epidemiologic studies have demonstrated that there are important differences in risk factors for complete and partial mole.
  • Complete moles are now increasingly being diagnosed in the first trimester, affecting their clinical presentation and pathologic characteristics.
  • While important advances have been made in chemotherapy, it is now recognized that etoposide is associated with a risk of second tumors.
  • Several studies have advanced understanding of the molecular biology of gestational trophoblastic disease, and this is important for the eventual development of new and innovative therapy.
  • [MeSH-minor] Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Chorionic Gonadotropin, beta Subunit, Human / blood. Etoposide / adverse effects. Etoposide / therapeutic use. Female. Humans. Incidence. Pregnancy. Prognosis. Risk Factors

  • Genetic Alliance. consumer health - Gestational Trophoblastic Disease.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11027078.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Chorionic Gonadotropin, beta Subunit, Human; 6PLQ3CP4P3 / Etoposide
  • [Number-of-references] 60
  •  go-up   go-down


18. Ozalp SS: Regional perspectives on gestational trophoblastic disease in Turkey. J Reprod Med; 2008 Aug;53(8):639-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epidemiologic study was performed to determine the frequency of hydatidiform mole (HM) in a rural part of Turkey.
  • Methotrexate was the single-agent chemotherapy used most frequently.
  • With regard to first-line combined chemotherapy, MAC (methotrexate, actinomycin, chlorambucil) was the preferred combination.
  • From more recent studies, EMA-CO is the first-line combination chemotherapy.
  • [MeSH-major] Hydatidiform Mole / epidemiology. Uterine Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diet. Female. Humans. Incidence. Neoplasm Recurrence, Local. Neoplasm Staging. Pregnancy. Rural Population. Socioeconomic Factors. Turkey / epidemiology. Young Adult


19. Wielsma S, Kerkmeijer L, Bekkers R, Pyman J, Tan J, Quinn M: Persistent trophoblast disease following partial molar pregnancy. Aust N Z J Obstet Gynaecol; 2006 Apr;46(2):119-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Human chorionic gonadotrophin (hCG) follow-up data were analysed retrospectively in all patients registered in the Hydatidiform Mole Registry at the Royal Women's Hospital, Melbourne from January 1992 to January 2001 to determine the risk of persistent trophoblast disease following partial molar pregnancy and to review the present follow-up protocol of patients suffering from partial hydatidiform molar pregnancy (PHM).
  • METHODS: Demographic factors were determined for all 344 cases with a review diagnosis of PHM, included age, history of previous hydatidiform mole, gestation length, hCG levels and compliance with follow-up.
  • FINDINGS: Six of the 344 patients diagnosed with PHM required treatment with single-agent methotrexate and folinic acid rescue.
  • All six patients achieved and maintained a complete biochemical remission after chemotherapy. hCG regression assays were analysed for 235 patients: 225 patients had at least one normal hCG measurement during follow-up, of whom 152 (64.7%) patients obtained normal values within 2 months after evacuation.
  • All patients obtained normal levels within 32 weeks after evacuation of the partial hydatidiform mole.
  • No patient who achieved normal hCG levels required chemotherapy because of a recurrent gestational trophoblastic tumour.
  • RECOMMENDATIONS: This study indicates that 1.7% of all partial mole pregnancy patients needed treatment for malignant sequelae.
  • In contrast, no patient diagnosed with partial mole had a biochemical or clinical relapse after achieving normal levels of hCG, consistent with previous studies.
  • Patients who have had a partial hydatidiform mole should be followed by hCG assays until normal levels are achieved and then follow-up can be safely discontinued.
  • [MeSH-major] Chorionic Gonadotropin / blood. Hydatidiform Mole / diagnosis. Methotrexate / therapeutic use. Neoplasm Recurrence, Local / diagnosis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Adult. Australia. Biomarkers, Tumor / blood. Female. Follow-Up Studies. Gestational Age. Humans. Maternal Age. Parity. Pregnancy. Pregnancy Complications, Neoplastic / diagnosis. Pregnancy Complications, Neoplastic / drug therapy. Pregnancy Outcome. Registries. Retrospective Studies. Risk Assessment. Trophoblastic Neoplasms / diagnosis. Trophoblastic Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Aust N Z J Obstet Gynaecol. 2006 Jun;46(3):179. Wiesma, Sabien [corrected to Wielsma, Sabien]
  • (PMID = 16638033.001).
  • [ISSN] 0004-8666
  • [Journal-full-title] The Australian & New Zealand journal of obstetrics & gynaecology
  • [ISO-abbreviation] Aust N Z J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


20. Nizam K, Haider G, Memon N, Haider A: Gestational trophoblastic disease: experience at Nawabshah Hospital. J Ayub Med Coll Abbottabad; 2009 Jan-Mar;21(1):94-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Gestational Trophoblastic Disease (GTD) is a heterogeneous group of diseases that includes partial and complete hydatidiform mole, invasive mole, choriocarcinoma and placental site trophoblastic tumour.
  • METHODS: The case records of all the gestational trophoblastic cases during study period were analysed regarding their history, clinical examination, investigations, treatment and follow-up.
  • The main outcomes were measured in terms of duration, antecedent pregnancy, investigations, treatment and the follow-up.
  • Of these 30 cases, 21 (70%) patients had hydatidiform mole, 7 (23.3%) patients had invasive disease and 2 (6.6%) patients had choriocarcinoma.
  • Twenty three patients (76.6%) received chemotherapy while 25 (83.3%) patients had suction evacuation and 4 (13.3%) patients underwent hysterectomy.
  • Hydatidiform mole was the commonest type of trophoblastic disease in these patients.
  • [MeSH-minor] Adolescent. Adult. Choriocarcinoma / diagnosis. Choriocarcinoma / epidemiology. Choriocarcinoma / therapy. Chorionic Gonadotropin, beta Subunit, Human / blood. Female. Humans. Hydatidiform Mole / diagnosis. Hydatidiform Mole / epidemiology. Hydatidiform Mole / therapy. Hydatidiform Mole, Invasive / diagnosis. Hydatidiform Mole, Invasive / epidemiology. Hydatidiform Mole, Invasive / therapy. Incidence. Pakistan / epidemiology. Pregnancy. Retrospective Studies. Trophoblastic Tumor, Placental Site / diagnosis. Trophoblastic Tumor, Placental Site / epidemiology. Trophoblastic Tumor, Placental Site / therapy. Uterine Neoplasms / diagnosis. Uterine Neoplasms / epidemiology. Uterine Neoplasms / therapy. Young Adult

  • Genetic Alliance. consumer health - Gestational Trophoblastic Disease.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20364752.001).
  • [ISSN] 1025-9589
  • [Journal-full-title] Journal of Ayub Medical College, Abbottabad : JAMC
  • [ISO-abbreviation] J Ayub Med Coll Abbottabad
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human
  •  go-up   go-down


21. Xue Y, Zhang J, Wu TX, An RF: Combination chemotherapy for high-risk gestational trophoblastic tumour. Cochrane Database Syst Rev; 2006;(3):CD005196
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy for high-risk gestational trophoblastic tumour.
  • BACKGROUND: Gestational trophoblastic disease (GTD) includes gestational trophoblastic tumour and hydatidiform mole.
  • A number of chemotherapy regimens are used for treating the disease, such as methotrexate, actinomycin D and cyclophosphamide (MAC), methotrexate, actinomycin D, cyclophosphamide, doxorubicin, melphalan, hydroxyurea and vincristine (CHAMOC), etoposide, methotrexate and actinomycin (EMA) plus cyclophosphamide and vincristine (CO) (EMA-CO), etoposide, methotrexate and actinomycin (EMA) plus etoposide and cisplatin(EP) (EMA-EP).
  • The efficacy of these drugs has not been systematically reviewed.
  • OBJECTIVES: To determine the efficacy and safety of combination chemotherapy in treating high-risk GTT.
  • SELECTION CRITERIA: The review included randomized controlled trials (RCTs) or quasi-RCTs of combination chemotherapy for treating high-risk GTT.
  • Patients with placental-site trophoblastic tumour (PSTT), who had received chemotherapy in the previous two weeks, or patients with chemotherapy intolerance were excluded.
  • AUTHORS' CONCLUSIONS: The methodological limitations of the included study prevent any firm conclusions about the best combination chemotherapy regimen for high-risk GTT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gestational Trophoblastic Disease / drug therapy
  • [MeSH-minor] Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Hydatidiform Mole / drug therapy. Hydroxyurea / administration & dosage. Leucovorin / administration & dosage. Methotrexate / administration & dosage. Pregnancy. Trophoblastic Tumor, Placental Site / drug therapy. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2009;(2):CD005196 [19370618.001]
  • (PMID = 16856085.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; X6Q56QN5QC / Hydroxyurea; YL5FZ2Y5U1 / Methotrexate; CHAMOMA protocol
  • [Number-of-references] 40
  •  go-up   go-down


22. Matsui H, Iitsuka Y, Yamazawa K, Tanaka N, Mitsuhashi A, Seki K, Sekiya S: Criteria for initiating chemotherapy in patients after evacuation of hydatidiform mole. Tumour Biol; 2003 May-Jun;24(3):140-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Criteria for initiating chemotherapy in patients after evacuation of hydatidiform mole.
  • OBJECTIVES: To evaluate the spontaneous regression curve of serum human chorionic gonadotropin (hCG) in patients with an uneventful course after evacuation of hydatidiform mole and to compare the criteria for initiating chemotherapy in patients after evacuation of mole.
  • METHODS: From 1986 to 2001, 608 patients were followed at our department after evacuation of mole.
  • RESULTS: After evacuation of mole, the titers of serum hCG decreased constantly, and 90% of patients with an uneventful course were within normal range within 16 weeks.
  • Moreover, 39 (9.0%) and 15 patients (3.5%) with an uneventful course might have been diagnosed with gestational trophoblastic tumor and received needless chemotherapy based on the normal regression curve established by the Japan Society of Obstetrics and Gynecology or the US criteria of 4 consecutive plateauing or rising hCG values, respectively.
  • CONCLUSIONS: Our more selective criteria for initiating chemotherapy in patients after evacuation of mole, i.e. hCG of 10,000 mIU/ml at 5 weeks, 1,000 mIU/ml at 8 weeks and nondetectable levels at 24 weeks after evacuation of mole, may be safe and acceptable in the management of patients after evacuation of mole.
  • [MeSH-major] Chorionic Gonadotropin / blood. Gestational Trophoblastic Disease / drug therapy. Gestational Trophoblastic Disease / surgery. Hydatidiform Mole / drug therapy. Hydatidiform Mole / surgery
  • [MeSH-minor] Female. Humans. Immunoenzyme Techniques. Pregnancy. Radioimmunoassay. Time Factors

  • Genetic Alliance. consumer health - Hydatidiform mole.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger AG, Basel
  • (PMID = 14610317.001).
  • [ISSN] 1010-4283
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin
  •  go-up   go-down


23. Sasaki S, Sasaki Y, Iino K: Recurrent gestational trophoblastic disease in a case of suspected quiescent gestational trophoblastic disease: a case report. J Reprod Med; 2010 Jul-Aug;55(7-8):317-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • GTD is managed well in Japan according to Japanese guidelines for the treatment of GTD, and we have almost conquered this disease during recent decades.
  • Many young doctors now have little opportunity to see typical classic mole and participate in the management of GTD during their residency training.
  • CASE: The patient was a 46-year-old woman, G3, P2, A1, who underwent dilation and curettage for complete mole 7 years earlier. hCG elevated during follow-up, and a 50-mg methotrexate single injection was given. hCG decreased to 20-30 mIU/mL, but it then plateaued for 3 months.
  • Three years and 3 months later beta-hCG went up to 3.1 ng/mL, but magnetic resonance imaging and computed tomography scans did not show any evidence of tumor.
  • We emphasize that sufficient initial chemotherapy is very important to reduce the risk of recurrence.
  • [MeSH-major] Choriocarcinoma / diagnosis. Hydatidiform Mole / pathology. Neoplasms, Second Primary / diagnosis. Uterine Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Chorionic Gonadotropin / blood. Dilatation and Curettage. Etoposide / therapeutic use. Female. Humans. Methotrexate / therapeutic use. Middle Aged. Pregnancy

  • Genetic Alliance. consumer health - Gestational Trophoblastic Disease.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20795345.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Chorionic Gonadotropin; 6PLQ3CP4P3 / Etoposide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


24. Steigrad SJ, Robertson G, Kaye AL: Serial hCG and ultrasound measurements for predicting malignant potential in multiple pregnancies associated with complete hydatidiform mole: a report of 2 cases. J Reprod Med; 2004 Jul;49(7):554-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serial hCG and ultrasound measurements for predicting malignant potential in multiple pregnancies associated with complete hydatidiform mole: a report of 2 cases.
  • BACKGROUND: Multiple pregnancy complicated by the presence of a complete hydatidiform mole (CHM) is a rare clinical entity.
  • The patient was treated with single-agent chemotherapy, with complete resolution.
  • [MeSH-major] Chorionic Gonadotropin, beta Subunit, Human / blood. Hydatidiform Mole / ultrasonography. Pregnancy Complications, Neoplastic / ultrasonography. Pregnancy, Multiple. Uterine Neoplasms / ultrasonography

  • Genetic Alliance. consumer health - Hydatidiform mole.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15305827.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human
  •  go-up   go-down


25. Andreani V, Richard MA, Blaise D, Gouvernet J, Grob JJ: Naevi in allogeneic bone marrow transplantation recipients: the effect of graft-versus-host disease on naevi. Br J Dermatol; 2002 Sep;147(3):433-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Non-melanoma skin carcinoma is more common in transplant recipients, probably because of immunosuppression.
  • An increased risk of developing melanoma could be a late effect of transplantation.
  • The number of naevi, which is a risk marker for melanoma, is increased in renal transplant recipients of all ages and may be related to immunosuppression.
  • The risk of melanoma has been suspected to be particularly high after bone marrow transplantation.
  • OBJECTIVE: To assess whether aBMT exposes an individual to a particularly high risk of melanoma, using naevi as a surrogate measure of the risk.
  • In exploratory subgroup case-control comparisons and with the general linear model, patients who were conditioned with a combination of two alkylating drugs at high doses, and patients who had an aBMT before the age of 20 years tended to have a higher count of naevi (P = 0.002 and P = 0.06, respectively).
  • Conversely, there was a trend in favour of a lower count of naevi in patients with diffuse skin lesions of chronic GVHD (P = 0.01).
  • These data were corroborated by multivariate analysis, which showed that conditioning with high-dose chemotherapy, the absence of severe chronic cutaneous GVHD and a young age at transplantation were the main variables that independently predicted an excess of naevi.
  • CONCLUSIONS: This study of aBMT patients confirms that chemotherapy stimulates naevus growth.
  • It also suggests for the first time that diffuse lesions of chronic cutaneous GVHD are associated with a decreased number of naevi.
  • Whether allo-immunity, chronic skin inflammation or the masking of naevi by pigmentation and fibrosis is responsible for the decreased number of naevi requires further investigation.
  • With respect to the long-term risk of melanoma in aBMT recipients, our results support an increased risk particularly when aBMT is performed at a young age, and when conditioning is with high doses of alkylating drugs.
  • [MeSH-major] Bone Marrow Transplantation / adverse effects. Graft vs Host Disease / complications. Nevus / etiology. Skin Neoplasms / etiology


26. Driessen WH, Fujii N, Tamamura H, Sullivan SM: Development of peptide-targeted lipoplexes to CXCR4-expressing rat glioma cells and rat proliferating endothelial cells. Mol Ther; 2008 Mar;16(3):516-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The substitution of the targeting lipid at increasing mole percentages in the place of helper lipids yielded a progressive increase in reporter gene expression, reaching a maximum of 2.5 times the control value at 20 mol% of ligand.
  • [MeSH-minor] Animals. Blood Vessels / cytology. Blood Vessels / drug effects. Blood Vessels / metabolism. Cell Line, Tumor. Cell Proliferation. Cells, Cultured. Citrulline / analogs & derivatives. Citrulline / chemistry. Endothelium, Vascular / cytology. Endothelium, Vascular / metabolism. Gene Expression / drug effects. Genetic Vectors / chemistry. Genetic Vectors / genetics. Glioma / genetics. Glioma / pathology. Naphthalenes / chemistry. Organ Culture Techniques. Phospholipids / chemistry. Rats. Vascular Endothelial Growth Factor A / pharmacology

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18195720.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 4-fluorobenzoyl-RR-(L-3-(2-naphthyl)alanine)-CYEK-(L-citrulline)-PYR-(L-citrulline)-CR; 0 / Naphthalenes; 0 / Peptides; 0 / Phospholipids; 0 / Receptors, CXCR4; 0 / Vascular Endothelial Growth Factor A; 29VT07BGDA / Citrulline
  •  go-up   go-down


27. Dhall G, Ginsburg HB, Bodenstein L, Fefferman NR, Greco MA, Chang MW, Gardner S: Thymoma in children: report of two cases and review of literature. J Pediatr Hematol Oncol; 2004 Oct;26(10):681-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Surgery is the treatment of choice for stage I and stage II tumors.
  • Chemotherapy is reserved for patients with refractory or metastatic disease.
  • However, radiation therapy is not an attractive option for children due to its side-effects on developing organs.
  • One of the patients also has nevus sebaceous.
  • [MeSH-minor] Adolescent. Cell Transformation, Neoplastic. Child. Chromosome Disorders / complications. Chromosomes, Human, Pair 12. Chromosomes, Human, Pair 6. Dyspnea / etiology. Epithelial Cells / pathology. Female. Hamartoma / complications. Humans. Intellectual Disability / complications. Male. Neoplasm Staging. Remission Induction. Skin Diseases / complications. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15454843.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 34
  •  go-up   go-down


28. Singh A, Ariatti M, Singh M, Hawtrey A, Naidoo R: Biotin-directed assembly of targeted modular lipoplexes and their transfection of human hepatoma cells in vitro. Drug Deliv; 2010 Aug;17(6):426-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dibiotinylated asialoorosomucoid was attached to cationic liposomes constructed from 3beta[N-(N',N'-dimethylaminopropane)-carbamoyl] cholesterol (Chol-T):dioleoylphosphatidylethanolamine:biotinylcholesterylformylhydrazide (MSB1) (48:50:2 mole ratio) through streptavidin interposition.
  • The streptavidin-biotin interaction has been applied for the first time to the assembly of hepatocyte-targeted lipoplexes that display asialoorosomucoid and that are well tolerated by a human hepatoma cell line in which transfection is demonstrably achieved by receptor mediation.
  • [MeSH-major] Biotin / metabolism. Carcinoma, Hepatocellular / metabolism. Genetic Therapy / methods. Liver Neoplasms / metabolism. Nanostructures / chemistry. Transfection / methods. Transgenes
  • [MeSH-minor] Asialoglycoprotein Receptor / metabolism. Asialoglycoproteins / adverse effects. Asialoglycoproteins / antagonists & inhibitors. Asialoglycoproteins / chemistry. Asialoglycoproteins / metabolism. Biotinylation. Cell Proliferation / drug effects. Cholesterol / adverse effects. Cholesterol / analogs & derivatives. Cholesterol / chemistry. Fetuins. Gene Transfer Techniques. Genes, Reporter. Hep G2 Cells. Humans. Ligands. Liposomes. Orosomucoid / adverse effects. Orosomucoid / analogs & derivatives. Orosomucoid / antagonists & inhibitors. Orosomucoid / chemistry. Orosomucoid / metabolism. Phosphatidylethanolamines / adverse effects. Phosphatidylethanolamines / chemistry. Plasmids / adverse effects. Plasmids / analysis. Plasmids / genetics. Plasmids / metabolism. Streptavidin / adverse effects. Streptavidin / metabolism. Streptavidin / therapeutic use. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • Hazardous Substances Data Bank. BIOTIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20469969.001).
  • [ISSN] 1521-0464
  • [Journal-full-title] Drug delivery
  • [ISO-abbreviation] Drug Deliv
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Asialoglycoprotein Receptor; 0 / Asialoglycoproteins; 0 / Fetuins; 0 / Ligands; 0 / Liposomes; 0 / Orosomucoid; 0 / Phosphatidylethanolamines; 0 / alpha-Fetoproteins; 0 / asialofetuin; 0 / asialoorosomucoid; 6SO6U10H04 / Biotin; 76391-83-8 / 1,2-dielaidoylphosphatidylethanolamine; 9013-20-1 / Streptavidin; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


29. Sáez Rodríguez M, Rodríguez-Martin M, Carnerero A, Sidro M, Rodríguez F, Cabrera R, Guimerá F, García M, Sánchez R, Noda A: Naevus lipomatosus cutaneous superficialis on the nose. J Eur Acad Dermatol Venereol; 2005 Nov;19(6):751-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Naevus lipomatosus cutaneous superficialis on the nose.
  • Naevus lipomatosus cutaneous superficialis (NLCS) is an uncommon hamartomatous lesion with an exceptional presentation on the face.
  • We report the case of an elderly patient who presented with a classic type of NLCS on the right nasal orifice.
  • [MeSH-major] Lipomatosis / diagnosis. Nevus / diagnosis. Nose Neoplasms / diagnosis
  • [MeSH-minor] Administration, Inhalation. Aged. Diagnosis, Differential. Humans. Male. Rhinitis, Allergic, Perennial / drug therapy. Steroids / administration & dosage

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Moles.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16268886.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Steroids
  •  go-up   go-down


30. Requena L, de la Cruz A, Moreno C, Sangüeza O, Requena C: Animal type melanoma: a report of a case with balloon-cell change and sentinel lymph node metastasis. Am J Dermatopathol; 2001 Aug;23(4):341-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Animal type melanoma: a report of a case with balloon-cell change and sentinel lymph node metastasis.
  • Animal type melanoma is a rare histopathologic variant of melanoma characterized by sheets and nodules of heavily pigmented epithelioid melanocytes that involve the entire thickness of the dermis.
  • This human neoplasm mimics melanocytic neoplasms seen in gray horses and laboratory animals; thus, is termed animal type melanoma.
  • We report an example of animal type melanoma on the back of a 27-year-old man.
  • The lesion showed areas of melanoma in situ, which ruled out the possibility of metastatic melanoma.
  • In some areas, neoplastic melanocytes exhibited a balloon-cell appearance; in others the neoplasm was composed of sheets and fascicles of heavily pigmented epithelioid melanocytes that permeated the entire dermis and extended into the dermal-subcutaneous interface, mimicking a cellular blue nevus.
  • A lymphoscintigraphy showed a sentinel lymph node in the right axilla and a subsequent axillary lymphadenectomy demonstrated that the architecture of the sentinel lymph node was effaced by metastatic melanoma.
  • The patient received adjuvant chemotherapy with inteferon alfa-2b and four months after this treatment the patient is alive and well, without evidence of recurrences or additional metastases.
  • [MeSH-major] Lymph Nodes / pathology. Melanoma. Skin Neoplasms
  • [MeSH-minor] Adult. Humans. Male. Melanoma, Experimental / pathology. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11481528.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Khashoggi TY: Prevalence of gestational trophoblastic disease. A single institution experience. Saudi Med J; 2003 Dec;24(12):1329-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To study the incidence and time trends of gestational trophoblastic disease in the Kingdom of Saudi Arabia (KSA).
  • RESULTS: Fifty-nine cases of hydatidiform mole (36 complete hydatidiform mole (CHM) and 23 partial hydatidiform mole (PHM) and 2 cases of choriocarcinoma were observed, out of 64,762 pregnancies registered at Security Forces Hospital, Riyadh, KSA, during an 11 year period.
  • The optimal management of this disease depends on prompt diagnosis, correct stratification of the risk category and appropriate treatment using various modalities such as chemotherapy and surgery.
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Chemotherapy, Adjuvant. Choriocarcinoma / epidemiology. Choriocarcinoma / pathology. Choriocarcinoma / therapy. Combined Modality Therapy. Female. Follow-Up Studies. Hospitals, Public. Humans. Hydatidiform Mole / epidemiology. Hydatidiform Mole / pathology. Hydatidiform Mole / therapy. Hysterectomy / methods. Maternal Age. Neoplasm Staging. Pregnancy. Pregnancy, High-Risk. Prevalence. Retrospective Studies. Risk Assessment. Saudi Arabia / epidemiology. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Gestational Trophoblastic Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14710278.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


32. Sato K, Sakakibara N, Hasegawa K, Minami H, Tsuji T: A preliminary report of the treatment of blue nevus with dermal injection of riboflavin and exposure to near-ultraviolet/visible radiation (ribophototherapy). J Dermatol Sci; 2000 May;23(1):22-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A preliminary report of the treatment of blue nevus with dermal injection of riboflavin and exposure to near-ultraviolet/visible radiation (ribophototherapy).
  • Dye lasers are useful for treating pigmented skin lesions, but their equipment is expensive and bulky.
  • A simple and cheap phototherapy would be acceptable to dermatologists for treating pigmented skin lesions such as nevus of Ota.
  • We investigated as a pilot study whether dermal injection of riboflavin and exposure to near-ultraviolet/visible radiation (ribophototherapy) decreases the dermal pigment of blue nevi which are recalcitrant to laser therapy.
  • The therapeutic efficacy was assessed by comparison of the amount of dermal pigment in hematoxylin-eosin specimens taken before and after treatment.
  • Pigmentation of the nevus became faint to the depth of 1 mm with little noticeable epidermal change after 21 treatments.
  • Ribophototherapy is hopeful for treating pigmented skin lesions.
  • [MeSH-major] Nevus, Blue / drug therapy. Photochemotherapy / methods. Photosensitizing Agents / administration & dosage. Riboflavin / administration & dosage. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Humans. Injections, Intradermal. Male. Microscopy, Electron. Skin Pigmentation / drug effects. Skin Pigmentation / radiation effects. Ultraviolet Therapy

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Riboflavin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10699761.001).
  • [ISSN] 0923-1811
  • [Journal-full-title] Journal of dermatological science
  • [ISO-abbreviation] J. Dermatol. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] IRELAND
  • [Chemical-registry-number] 0 / Photosensitizing Agents; TLM2976OFR / Riboflavin
  •  go-up   go-down


33. Feng FZ, Xiang Y, Wan XR, Yin SJ, Yang XY: [Clinical characteristics and management of gestational trophoblastic disease in women aged 50 years or more]. Zhonghua Fu Chan Ke Za Zhi; 2005 Sep;40(9):605-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The lesions included 5 hydatidiform moles (13%), 19 invasive moles (50%), 12 choriocarcinomas (32%) and 2 placenta site trophoblastic tumors (5%).
  • Twenty-three cases of hydatidiform moles were diagnosed at their first visit to the hospital, and 15 of them received prophylactic chemotherapy, of whom 10 progressed to invasive mole, 3 developed lung metastasis.
  • All of the other 8 cases without prophylactic chemotherapy progressed to malignant changes with metastasis of lung.
  • The use of prophylactic chemotherapy reduced the incidence of subsequent metastasis.
  • All of 38 cases received chemotherapy.
  • Once gestational trophoblastic disease in women aged 50 years or more is diagnosed, chemotherapy should be given as soon as possible.
  • [MeSH-major] Gestational Trophoblastic Disease / diagnosis. Gestational Trophoblastic Disease / drug therapy
  • [MeSH-minor] Choriocarcinoma / diagnosis. Choriocarcinoma / drug therapy. Choriocarcinoma / surgery. Female. Humans. Hydatidiform Mole / diagnosis. Hydatidiform Mole / drug therapy. Hydatidiform Mole / surgery. Middle Aged. Pregnancy. Prognosis. Retrospective Studies. Time Factors. Treatment Outcome. Uterine Hemorrhage / diagnosis

  • Genetic Alliance. consumer health - Gestational Trophoblastic Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16202316.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


34. Bakri YN, Ezzat A, Akhtar, Dohami, Zahrani: Malignant germ cell tumors of the ovary. Pregnancy considerations. Eur J Obstet Gynecol Reprod Biol; 2000 May;90(1):87-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients who conceived after treatment were identified and their reproductive outcome described.
  • Amongst the 22 patients who planned to conceive after conservative surgery, with or without post-operative adjuvant chemotherapy, 12 conceived (12/22) and achieved a total of 20 pregnancies.
  • Their outcomes included normal births (n=18) including one set of twins and hydatidiform moles (n=2).
  • However, the question remains as to whether pregnancy worsened the prognosis of non-dysgerminomatous germ cell tumors. (2) Recent platinum-based regimens of multiagent chemotherapy for germ cell tumors did not seem to affect fertility potential.
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Middle Aged. Neoplasm Staging. Pregnancy. Pregnancy Outcome. Reproductive History

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10767517.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] IRELAND
  •  go-up   go-down


35. Riadh BT, Abdellatif C, Wissal H, Leila A, Taher M, Abdelhamid K: Clinical analysis and management of gestational trophoblastic diseases: a 90 cases study. Int J Biomed Sci; 2009 Dec;5(4):321-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The aim of the study was to identify the incidence, diagnosis, therapeutic and histological particularities of molar pregnancies and to evaluate our management of gestational trophoblastic tumors (GTT) according to the recommendations of FIGO.
  • Patients whose condition required chemotherapy for GTT were attributed a FIGO/WHO score.
  • Treatment consisted in uterine evacuation by suction curettage.
  • Histological findings were complete mole in 66.66% of the cases and partial mole in 33.33% of the cases.
  • 81 patients (90%) achieved remission without chemotherapy and 9 patients (10%) had FIGO stage I GTT.
  • CONCLUSION: The practice of ultrasonography in the first trimester of pregnancy allows an early diagnosis of molar pregnancy and an adequate treatment and follow-up.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23675154.001).
  • [ISSN] 1550-9702
  • [Journal-full-title] International journal of biomedical science : IJBS
  • [ISO-abbreviation] Int J Biomed Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3614797
  • [Keywords] NOTNLM ; chemotherapy / gestational trophoblastic tumors / human chorionic gonadotropin / hydatiform mole / ultrasonography
  •  go-up   go-down


36. Chiu PM, Ngan YS, Khoo US, Cheung AN: Apoptotic activity in gestational trophoblastic disease correlates with clinical outcome: assessment by the caspase-related M30 CytoDeath antibody. Histopathology; 2001 Mar;38(3):243-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: The objective of this study was to assess apoptotic activity in gestational trophoblastic disease (GTD) and its prognostic value in hydatidiform mole (HM).
  • The M30 index of those HM which spontaneously regressed was significantly higher than those HM which developed persistent disease requiring chemotherapy (P < 0.001).
  • [MeSH-minor] Abortion, Spontaneous / metabolism. Apoptosis. Choriocarcinoma / metabolism. Female. Follow-Up Studies. Humans. Hydatidiform Mole / metabolism. Hydatidiform Mole / pathology. In Situ Nick-End Labeling. Pregnancy. Prognosis. Trophoblastic Tumor, Placental Site / metabolism. Trophoblastic Tumor, Placental Site / pathology

  • Genetic Alliance. consumer health - Gestational Trophoblastic Disease.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11260306.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 68238-35-7 / Keratins; EC 3.4.22.- / Caspases
  •  go-up   go-down


37. Avnir Y, Ulmansky R, Wasserman V, Even-Chen S, Broyer M, Barenholz Y, Naparstek Y: Amphipathic weak acid glucocorticoid prodrugs remote-loaded into sterically stabilized nanoliposomes evaluated in arthritic rats and in a Beagle dog: a novel approach to treating autoimmune arthritis. Arthritis Rheum; 2008 Jan;58(1):119-29
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We undertook this study to determine whether a novel approach could overcome the limitations that have thus far prevented the clinical use of these formulations: low drug:lipid ratio, low encapsulation efficiency, and lack of controlled release.
  • RESULTS: Our liposome formulation exhibited high encapsulation efficiency (94%) and a high drug:lipid mole ratio (0.41) and demonstrated controlled release of the encapsulated GC during systemic circulation and in inflamed paws in rats with adjuvant-induced arthritis.
  • Finally, we demonstrated the superior therapeutic efficacy of our liposome formulation over that of free GCs in arthritic rats, both in early and in peak disease stages.
  • The unique loading method, which also leads to controlled release, improves the therapeutic effect both systemically and locally.
  • Such a development has great potential for improving GC therapy.
  • [MeSH-major] Arthritis, Experimental / drug therapy. Glucocorticoids / pharmacology. Liposomes / pharmacology. Nanostructures. Prodrugs / pharmacology
  • [MeSH-minor] Acids. Animals. Delayed-Action Preparations. Dogs. Drug Delivery Systems. Female. Rats. Rats, Inbred Lew. Tissue Distribution

  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arthritis Rheum. 2008 Jan;58(1):2-4 [18163490.001]
  • (PMID = 18163482.001).
  • [ISSN] 0004-3591
  • [Journal-full-title] Arthritis and rheumatism
  • [ISO-abbreviation] Arthritis Rheum.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acids; 0 / Delayed-Action Preparations; 0 / Glucocorticoids; 0 / Liposomes; 0 / Prodrugs
  •  go-up   go-down


38. Garzó V: Tracer diffusion in granular shear flows. Phys Rev E Stat Nonlin Soft Matter Phys; 2002 Aug;66(2 Pt 1):021308
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The analysis is made from a perturbation solution of the Boltzmann kinetic equation through first order in the gradient of the mole fraction of tracer particles.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12241171.001).
  • [ISSN] 1539-3755
  • [Journal-full-title] Physical review. E, Statistical, nonlinear, and soft matter physics
  • [ISO-abbreviation] Phys Rev E Stat Nonlin Soft Matter Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Kim SJ, Na YJ, Jung SG, Kim CJ, Bae SN, Lee C: Management of high-risk hydatidiform mole and persistent gestational trophoblastic neoplasia: the Korean experience. J Reprod Med; 2007 Sep;52(9):819-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of high-risk hydatidiform mole and persistent gestational trophoblastic neoplasia: the Korean experience.
  • OBJECTIVE: To test the efficacy of a new scoring system to differentiate high-risk hydatidiform mole (H-mole) and initiate early selective postmolar chemotherapy.
  • STUDY DESIGN: According to Kim's scoring system, 262 patients were identified as high-risk H-mole patients.
  • Fifty (19.1%) received early chemotherapy, and the rest constituted the control group.
  • Salvage therapy with etoposide, methotrexate, actinomycin D/etoposide, cisplatin (EMA/EP) and taxol, cisplatin/taxol, etoposide (TP/TE) was applied in 21 cases of ultra-high-risk GTT.
  • RESULTS: None of the 50 cases in the early chemotherapy group progressed to persistent GTT.
  • However, 58.9% in the control group developed GTT with 8.0% drug resistance.
  • Of those receiving salvage therapy in the 21 ultra-high-risk GTT cases resistant to EMA/CO, 10 of 14 (71%) receiving EMA/EP and 4 of 7 (57.1%) receiving TP/TE achieved remission.
  • CONCLUSION: Early postmolar chemotherapy for high-risk H-mole is effective in preventing progression to persistent GTT and treatment failure.
  • Ultra-high-risk GTT should be approached with multimodal treatment, including EMA/EP and TP/TE regimens.
  • [MeSH-major] Hydatidiform Mole / drug therapy. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / prevention & control. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Case-Control Studies. Cisplatin / administration & dosage. Dactinomycin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Korea. Methotrexate / administration & dosage. Middle Aged. Paclitaxel / administration & dosage. Pregnancy. Prospective Studies. Registries. Retrospective Studies. Risk Factors. Salvage Therapy. Severity of Illness Index

  • Genetic Alliance. consumer health - Hydatidiform mole.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17939600.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 6PLQ3CP4P3 / Etoposide; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


40. Kim YS, Song R, Chung HC, Jun MJ, Sohn YS: Coordination modes vs. antitumor activity: synthesis and antitumor activity of novel platinum(II) complexes of N-substituted amino dicarboxylic acids. J Inorg Biochem; 2004 Jan;98(1):98-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The (O,O')/(O,N)-isomeric mixture with the mole ratio of 80/20 exhibited excellent antitumor activity while the pure (O,N)-isomer was only marginally active.
  • [MeSH-minor] Animals. Cell Line, Tumor. Drug Screening Assays, Antitumor. Humans. Hydrophobic and Hydrophilic Interactions. Inhibitory Concentration 50. Isomerism. Leukemia L1210 / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14659638.001).
  • [ISSN] 0162-0134
  • [Journal-full-title] Journal of inorganic biochemistry
  • [ISO-abbreviation] J. Inorg. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amino Acids, Dicarboxylic; 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds
  •  go-up   go-down


41. Apikian M, Goodman G: Intralesional 5-fluorouracil in the treatment of keloid scars. Australas J Dermatol; 2004 May;45(2):140-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intralesional 5-fluorouracil in the treatment of keloid scars.
  • The second patient developed a keloid scar on her chest following excision of a mole.
  • Multiple treatments were required to obtain resolution of the keloid scars.
  • Improvement was maintained in both patients at 1 year post treatment.
  • [MeSH-major] Antimetabolites / therapeutic use. Betamethasone / analogs & derivatives. Fluorouracil / therapeutic use. Keloid / drug therapy
  • [MeSH-minor] Acne Keloid / drug therapy. Adult. Facial Dermatoses / drug therapy. Female. Follow-Up Studies. Glucocorticoids / administration & dosage. Glucocorticoids / therapeutic use. Humans. Injections, Intralesional. Male. Thorax

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. BETAMETHASONE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15068466.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antimetabolites; 0 / Glucocorticoids; 7BK02SCL3W / betamethasone sodium phosphate; 9842X06Q6M / Betamethasone; U3P01618RT / Fluorouracil
  •  go-up   go-down


42. McGrath S, Short D, Harvey R, Schmid P, Savage PM, Seckl MJ: The management and outcome of women with post-hydatidiform mole 'low-risk' gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU l(-1). Br J Cancer; 2010 Mar 2;102(5):810-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The management and outcome of women with post-hydatidiform mole 'low-risk' gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU l(-1).
  • BACKGROUND: Gestational trophoblastic neoplasia (GTN) after a hydatidiform mole is either treated with single- or multi-agent chemotherapy determined by a multifactorial scoring system.
  • Women with human chorionic gonadotrophin (hCG) levels >100 000 IU l(-1) can remain within the low-risk/single-agent category and usually choose one drug therapy.
  • Here we compare the success and duration of single- vs multi-agent chemotherapy in this patient group.
  • METHODS: Between 1980 and 2008, 65 women had a pre-treatment hCG >100 000 IU l(-1) and were low risk.
  • The initial hCG level, treatment regimens, changes and duration and overall survival were recorded.
  • RESULTS: Of 37 patients starting low-risk/single-agent treatment, 11 (29.7%) were treated successfully, whereas 26 (70.3%) required additional multi-agent chemotherapy to achieve complete remission (CR).
  • Combination chemotherapy was initially commenced in 28 women, and 2 (7%) required additional drugs for CR.
  • The overall duration of therapy for those commencing and completing single- or multi-agent chemotherapy was 130 and 123 days (P=0.78), respectively.
  • The median-treatment duration for patients commencing single-agent but changing to multi-agent chemotherapy was 13 days more than those receiving high-risk treatment alone (136 vs 123 days; P=0.07).
  • All 3 patients with an initial hCG >400 000 IU l(-1) and treated with single-agent therapy developed drug resistance.
  • CONCLUSION: Low-risk post-molar GTN patients with a pre-treatment hCG >100 000 and <400 000 IU l(-1) can be offered low-risk single-agent therapy, as this will cure 30%, is relatively non-toxic and only prolongs treatment by 2 weeks if a change to combination agents is required.
  • Patients whose hCG is >400 000 IU l(-1) should receive multi-agent chemotherapy from the outset.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chorionic Gonadotropin / blood. Gestational Trophoblastic Disease / drug therapy
  • [MeSH-minor] Adult. Female. Humans. Neoplasm Staging. Pregnancy. Prognosis. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Hydatidiform mole.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Feb;18(4):854-9 [10673528.001]
  • [Cites] Gynecol Oncol. 2004 Jul;94(1):204-7 [15262143.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1838-44 [11919242.001]
  • [Cites] J Reprod Med. 2004 Aug;49(8):643-54 [15457855.001]
  • [Cites] Cancer. 1976 Sep;38(3):1373-85 [182354.001]
  • [Cites] Cancer. 1982 Nov 15;50(10):2024-7 [6290020.001]
  • [Cites] Tumori. 1987 Jun 30;73(3):309-13 [3037744.001]
  • [Cites] Gynecol Oncol. 1988 Nov;31(3):439-44 [2846414.001]
  • [Cites] Br J Obstet Gynaecol. 1989 Jul;96(7):795-802 [2548568.001]
  • [Cites] Br J Obstet Gynaecol. 1991 Jun;98(6):550-7 [1651757.001]
  • [Cites] Eur J Gynaecol Oncol. 1993;14(6):461-5 [7514124.001]
  • [Cites] J Clin Oncol. 1996 Oct;14(10):2769-73 [8874338.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1204-7 [9849480.001]
  • [Cites] Gynecol Oncol. 2004 Dec;95(3):423-9 [15581942.001]
  • [Cites] Aust N Z J Obstet Gynaecol. 2005 Apr;45(2):161-4 [15760322.001]
  • [Cites] Gynecol Oncol. 2005 Oct;99(1):251-2; author reply 252-3 [16137746.001]
  • [Cites] Int J Gynecol Cancer. 2006 May-Jun;16(3):1432-8 [16803542.001]
  • [Cites] Curr Opin Oncol. 2007 Sep;19(5):486-91 [17762576.001]
  • [Cites] BMJ. 2008;337:a1193 [18708429.001]
  • [Cites] Ann Oncol. 2008 Sep;19(9):1578-83 [18453518.001]
  • [Cites] Int J Gynaecol Obstet. 2008 Oct;103(1):33-7 [18632105.001]
  • [Cites] Lancet. 2000 Jul 1;356(9223):36-9 [10892763.001]
  • (PMID = 20160727.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin
  • [Other-IDs] NLM/ PMC2833242
  •  go-up   go-down


43. Niemann I, Sunde L, Petersen LK: Evaluation of the risk of persistent trophoblastic disease after twin pregnancy with diploid hydatidiform mole and coexisting normal fetus. Am J Obstet Gynecol; 2007 Jul;197(1):45.e1-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the risk of persistent trophoblastic disease after twin pregnancy with diploid hydatidiform mole and coexisting normal fetus.
  • OBJECTIVE: This study was undertaken to evaluate the risk of persistent trophoblastic disease and obstetric complications related to a multiple pregnancy comprising a diploid hydatidiform mole and normal cofetus(es).
  • STUDY DESIGN: From a database of 270 consecutively collected hydatidiform moles, 8 multiple and 154 singleton molar pregnancies were identified.
  • Molar and fetal ploidy was determined, and data on clinical features and chemotherapy were collected.
  • Five patients with diploid mole and coexisting fetus pregnancy chose to terminate their pregnancy, 2 aborted spontaneously, and 1 patient delivered a healthy child.
  • Two diploid mole and coexisting fetus pregnancies (25%) and 17% of the singleton molar pregnancies were followed by persistent trophoblastic disease (P = .63).
  • CONCLUSION: The risk of persistent trophoblastic disease after a diploid mole with coexisting fetus pregnancy is similar to that after a singleton molar pregnancy, and expectant management instead of therapeutic abortion can be pursued.
  • [MeSH-major] Hydatidiform Mole / complications. Pregnancy Complications, Neoplastic. Twins. Uterine Neoplasms / complications


44. Shimizu T, Yaegashi N: [Gestational trophoblastic tumors and recent clinical information]. Gan To Kagaku Ryoho; 2002 Aug;29(8):1363-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients who score as low-risk are treated with single agent chemotherapy, such as methotrexate (MTX), and patients refractory to MTX are treated with a combination chemotherapy, EMA/CO.
  • Patients who score as high-risk are treated with EMA/CO, and patients refractory to the first line chemotherapy may be successfully treated with EP/EMA.
  • Recent epidemiological data showed that women with complete hydatidiform moles could anticipate normal reproduction in the future.
  • Studies found that pregnancies after treatment of molar pregnancy resulted in 69% full-term, live births; 8% premature deliveries; 1% ectopic pregnancies, and 0.5% stillbirths.
  • Patients with hydatidiform mole were at increased risk of developing molar pregnancy in subsequent conceptions.
  • Partial hydatidiform moles were never previously proven to transform into choriocarcinoma; however, a recent study with molecular techniques clearly showed that partial moles could transform into choriocarcinoma.
  • All patients with suspected partial moles should be reviewed centrally and require hCG follow-up.
  • [MeSH-major] Trophoblastic Neoplasms / therapy. Uterine Neoplasms / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Contraceptives, Oral / adverse effects. Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Hydatidiform Mole / pathology. Methotrexate / administration & dosage. Pregnancy. Prognosis. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12214462.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Contraceptives, Oral; 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate; EMA-CO protocol; VP-P protocol
  • [Number-of-references] 15
  •  go-up   go-down


45. Wu SZ, Liu KS, Chu KS, Cheng KI, Kuei CH, Wang JJ, Tzeng JI: The depot of buprenorphine decanoate produced a dose-related long-lasting antinociceptive effect in guinea pigs. Acta Anaesthesiol Taiwan; 2006 Sep;44(3):161-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The antinociception of drugs was evaluated using the plantar test.
  • The blood concentrations of drugs were assayed using a high performance liquid chromatography.
  • Under an equi-mole basis of 0.6 micromol/kg, the durations of action of buprenorphine HCl and decanoate were 4 and 72 h, respectively.
  • [MeSH-minor] Animals. Delayed-Action Preparations. Dose-Response Relationship, Drug. Guinea Pigs. Injections, Intramuscular. Male. Pain / drug therapy

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Acta Anaesthesiol Taiwan. 2006 Sep;44(3):133-4 [17036999.001]
  • (PMID = 17037004.001).
  • [ISSN] 1875-4597
  • [Journal-full-title] Acta anaesthesiologica Taiwanica : official journal of the Taiwan Society of Anesthesiologists
  • [ISO-abbreviation] Acta Anaesthesiol Taiwan
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 0 / Delayed-Action Preparations; 40D3SCR4GZ / Buprenorphine
  •  go-up   go-down


46. González-Tortosa J, Ferri-Níguez B, Ros de San Pedro J: [Cerebellopontine angle meningeal melanocytoma: a benign tumor?]. Neurocirugia (Astur); 2009 Aug;20(4):372-9; discussion 379-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cerebellopontine angle meningeal melanocytoma: a benign tumor?].
  • [Transliterated title] Melanocitoma meníngeo del ángulo pontocerebeloso: un tumor benigno?
  • We report a case of a rare meningeal melanocytoma in the cerebellopontine angle.
  • The relevant literature is reviewed looking for the keys to establish preoperative diagnosis and to obtain information about its treatment and postsurgical management.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Cerebellopontine Angle / pathology. Melanocytes / pathology. Meningeal Neoplasms / pathology. Nevus / pathology
  • [MeSH-minor] Antineoplastic Agents, Alkylating / therapeutic use. Diagnosis, Differential. Disease Progression. Fatal Outcome. Gait Disorders, Neurologic / etiology. Hearing Loss, Sensorineural / etiology. Humans. Magnetic Resonance Imaging. Male. Melanoma / diagnosis. Melanoma / pathology. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neurilemmoma / diagnosis. Nitrosourea Compounds / therapeutic use. Organophosphorus Compounds / therapeutic use

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Moles.
  • Hazardous Substances Data Bank. Fotemustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19688139.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Nitrosourea Compounds; 0 / Organophosphorus Compounds; GQ7JL9P5I2 / fotemustine
  • [Number-of-references] 44
  •  go-up   go-down


47. Sivanesaratnam V: Management of gestational trophoblastic disease in developing countries. Best Pract Res Clin Obstet Gynaecol; 2003 Dec;17(6):925-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • While uterine suction is the preferred method of uterine evacuation of hydatidiform mole, complete evacuation was not achieved at the first attempt in 25% of cases.
  • Partial moles comprise 30% of all moles; these need follow up similar to that for complete moles as they are potentially malignant.
  • In the management of invasive moles, chemotherapy should not be withheld in the presence of metastases or failure of regression of hCG.
  • Prophylactic hysterectomy and prophylactic chemotherapy are not recommended.
  • However, in those patients with unsatisfactory hCG regression curves indicating 'at risk' in developing gestational trophoblastic neoplasia (GTN), 'selective preventive chemotherapy' appears appropriate.
  • Chemotherapy remains the main modality of treatment for GTN.
  • [MeSH-major] Developing Countries. Gestational Trophoblastic Disease / therapy
  • [MeSH-minor] Antineoplastic Agents / adverse effects. Brain Neoplasms / secondary. Choriocarcinoma / prevention & control. Female. Humans. Hydatidiform Mole / surgery. Hydatidiform Mole, Invasive / therapy. Hysterectomy / methods. Jaundice / etiology. Pregnancy. Risk Factors. Trophoblastic Tumor, Placental Site / surgery. Uterine Neoplasms / prevention & control. Uterine Neoplasms / surgery

  • Genetic Alliance. consumer health - Gestational Trophoblastic Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14614890.001).
  • [ISSN] 1521-6934
  • [Journal-full-title] Best practice & research. Clinical obstetrics & gynaecology
  • [ISO-abbreviation] Best Pract Res Clin Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 33
  •  go-up   go-down


48. Xue WC, Khoo US, Ngan HY, Chan KY, Chiu PM, Tsao SW, Cheung AN: Minichromosome maintenance protein 7 expression in gestational trophoblastic disease: correlation with Ki67, PCNA and clinicopathological parameters. Histopathology; 2003 Nov;43(5):485-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: To assess the proliferative activity of gestational trophoblastic disease (GTD) using one of the novel proliferation markers (MCM7) and to determine its prognostic value in hydatidiform mole (HM).
  • METHODS AND RESULTS: Immunohistochemical staining for MCM7 was performed on 122 samples of paraffin-embedded trophoblastic tissues including 22 normal first-trimester placentas, 12 term placentas, 12 spontaneous miscarriages (SM), 21 partial moles (PM), 44 complete hydatidiform moles (CM), and 11 choriocarcinomas (CCA).
  • Eighteen of the 65 patients with HM developed persistent trophoblastic disease (PTD) requiring chemotherapy.
  • There was no significant difference in MCM7 indices between the patients who developed PTD and those who did not (P = 0.312).

  • Genetic Alliance. consumer health - Gestational Trophoblastic Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14636275.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen
  •  go-up   go-down


49. Gillespie AM, Lidbury EA, Tidy JA, Hancock BW: The clinical presentation, treatment, and outcome of patients diagnosed with possible ectopic molar gestation. Int J Gynecol Cancer; 2004 Mar-Apr;14(2):366-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical presentation, treatment, and outcome of patients diagnosed with possible ectopic molar gestation.
  • The objective of this study was to determine the clinical presentation, treatment, and outcome of patients diagnosed with possible ectopic molar gestation registered with the Trophoblastic Disease Screening and Treatment Centre, Weston Park Hospital, Sheffield between 1986 and 2000.
  • Information regarding the relevant history of each patient and the clinical presentation, treatment, and outcomes of gestational trophoblastic disease (GTD) was determined by reviewing referral forms, case notes, and pro formas completed by the referring gynecologist.
  • Central histological review confirmed only six cases of GTD: three choriocarcinoma and three early complete moles.
  • Four patients subsequently required chemotherapy.
  • Chemotherapy may be required and the prognosis is excellent.
  • [MeSH-minor] England / epidemiology. Female. Humans. Pregnancy. Retrospective Studies. Risk Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15086739.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Wan X, Xiang Y, Yang X, Xin F, Yang N, Liu W: [Superselective arterial embolization for hemorrhage from malignant gestational trophoblastic tumor]. Zhonghua Fu Chan Ke Za Zhi; 2002 Jan;37(1):5-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: From February 1990 to June 2001, 31 patients (choriocarcinoma 24, invasive mole 7) with hemorrhage from malignant gestational trophoblastic tumor were treated with superselective arterial embolization.
  • Four patients had normal term delivery after successful superselective arterial embolization and chemotherapy.
  • [MeSH-major] Embolization, Therapeutic. Hemorrhage / therapy. Trophoblastic Neoplasms / complications. Uridine / analogs & derivatives
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Female. Humans. Pregnancy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11953054.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 4K0M952561 / 5-fluorouridine; WHI7HQ7H85 / Uridine
  •  go-up   go-down


51. Ma S, Xiang Y, Yang X: [Diagnosis and treatment of ectopic molar pregnancy]. Zhonghua Fu Chan Ke Za Zhi; 2001 Oct;36(10):618-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of ectopic molar pregnancy].
  • OBJECTIVE: To summerize the experience in the diagnosis and treatment of ectopic molar pregnancy.
  • METHODS: Clinical data of 3 cases of women with ectopic hydatidiform mole in Peking Union Medical College Hospital were analyzed retrospectively.
  • Regular chemotherapy and resection of drug-resistant focus are still the main methods of treatment.
  • CONCLUSIONS: Prophylactic chemotherapy for ectopic molar pregnancy should be emphasized.
  • It is very important to make an early diagnosis of malignant metastasis and to give a regular treatment for the patients.
  • [MeSH-major] Hydatidiform Mole / diagnosis. Hydatidiform Mole / therapy. Pregnancy, Ectopic / diagnosis. Pregnancy, Ectopic / therapy
  • [MeSH-minor] Angiography, Digital Subtraction. Antineoplastic Agents / therapeutic use. Female. Humans. Pregnancy. Ultrasonography, Doppler, Color

  • Genetic Alliance. consumer health - Ectopic Pregnancy.
  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ectopic Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16134527.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


52. Hosalkar HS, Jones DH, Offiah A, Hall C: Linear sebaceous naevus syndrome and resistant rickets. J Bone Joint Surg Br; 2003 May;85(4):578-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Linear sebaceous naevus syndrome and resistant rickets.
  • The association between vitamin-D-resistant rickets and linear sebaceous naevus syndrome is extremely rare.
  • The disturbances of metabolism of vitamin D and the effects of pharmacological treatment are also described.
  • [MeSH-major] Hypophosphatemia, Familial / complications. Nevus / complications. Sebaceous Gland Neoplasms / complications
  • [MeSH-minor] Calcitriol / therapeutic use. Child. Child, Preschool. Humans. Leg / radiography. Male. Pelvic Bones / radiography. Phosphates / therapeutic use. Syndrome

  • Genetic Alliance. consumer health - Rickets.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Moles.
  • Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Bone Joint Surg Br. 2004 Jan;86(1):151; author reply 151 [14765888.001]
  • (PMID = 12793567.001).
  • [ISSN] 0301-620X
  • [Journal-full-title] The Journal of bone and joint surgery. British volume
  • [ISO-abbreviation] J Bone Joint Surg Br
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Phosphates; FXC9231JVH / Calcitriol
  •  go-up   go-down


53. Khan F, Everard J, Ahmed S, Coleman RE, Aitken M, Hancock BW: Low-risk persistent gestational trophoblastic disease treated with low-dose methotrexate: efficacy, acute and long-term effects. Br J Cancer; 2003 Dec 15;89(12):2197-201
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The overall complete response rate without recurrence was 72% for first-line treatment and 95% for those who required second-line chemotherapy.
  • Eight women (3.2%) had recurrence following remission and two (0.8%) had new moles.
  • Only 10 women (4%) experienced grade III/IV toxicity during the first course of treatment and 13 women (5.2%) subsequently.
  • A total of 59 women (23.6%) required second-line chemotherapy; 48 women had methotrexate resistance, eight had methotrexate toxicity and an empirical decision to change therapy was made in three.
  • In all, 11 women (4.4%) had a hysterectomy before, during or after treatment; 141 women (56.4%) became pregnant following treatment: in 128 (90.7%), the outcome was successful.
  • Methotrexate with folinic acid rescue is an effective treatment for low-risk persistent trophoblastic disease.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Gestational Trophoblastic Disease / drug therapy. Methotrexate / therapeutic use. Neoplasm Recurrence, Local
  • [MeSH-minor] Adolescent. Adult. Drug Resistance, Neoplasm. Female. Humans. Leucovorin / therapeutic use. Middle Aged. Neoplasm Staging. Neoplasm, Residual. Pregnancy. Treatment Outcome. Vitamin B Complex / therapeutic use

  • Genetic Alliance. consumer health - Gestational Trophoblastic Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1992 Apr;45(1):40-5 [1318254.001]
  • [Cites] Gynecol Oncol. 1990 Jan;36(1):56-9 [2153091.001]
  • [Cites] Gynecol Oncol. 1994 Jul;54(1):76-9 [8020843.001]
  • [Cites] Am J Obstet Gynecol. 1995 Feb;172(2 Pt 1):574-9 [7856688.001]
  • [Cites] Postgrad Med J. 1995 Apr;71(834):244-5 [7784289.001]
  • [Cites] N Engl J Med. 1996 Dec 5;335(23):1740-8 [8929267.001]
  • [Cites] J Reprod Med. 1998 Jan;43(1):37-43 [9475148.001]
  • [Cites] Br J Cancer. 1999 Nov;81(6):1037-41 [10576662.001]
  • [Cites] Br J Cancer. 2000 Apr;82(8):1393-5 [10780516.001]
  • [Cites] Br J Cancer. 2000 May;82(9):1547-52 [10789722.001]
  • [Cites] Am J Obstet Gynecol. 2000 Dec;183(6):1579-82 [11120531.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1838-44 [11919242.001]
  • [Cites] Int J Gynaecol Obstet. 2002 Jun;77(3):285-7 [12065144.001]
  • [Cites] BJOG. 2003 Jun;110(6):555-9 [12798471.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] Gynecol Oncol. 1984 Sep;19(1):53-6 [6088370.001]
  • [Cites] Lancet. 1986 Sep 20;2(8508):673-7 [2876145.001]
  • [Cites] Obstet Gynecol. 1987 Mar;69(3 Pt 1):390-5 [3029641.001]
  • [Cites] Cancer. 1987 Nov 1;60(9):2173-6 [2449942.001]
  • [Cites] Acta Oncol. 1988;27(5):551-6 [2849467.001]
  • [Cites] Br J Obstet Gynaecol. 1989 Jul;96(7):795-802 [2548568.001]
  • [Cites] J Reprod Med. 1992 May;37(5):461-5 [1324312.001]
  • (PMID = 14676794.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 12001-76-2 / Vitamin B Complex; Q573I9DVLP / Leucovorin; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ PMC2395266
  •  go-up   go-down


54. Gayl Schweitzer V: Photofrin-mediated photodynamic therapy for treatment of aggressive head and neck nonmelanomatous skin tumors in elderly patients. Laryngoscope; 2001 Jun;111(6):1091-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photofrin-mediated photodynamic therapy for treatment of aggressive head and neck nonmelanomatous skin tumors in elderly patients.
  • OBJECTIVES/HYPOTHESIS: Aggressive nonmelanomatous skin tumors (basal cell carcinoma, squamous cell carcinoma, and Bowen's disease) of the head and neck often occur in Caucasian elderly patients because of prior history of radiation therapy for teenage acne and adenoid hypertrophy; severe solar-induced skin damage, basal cell nevus syndrome, and other genetic skin diseases; chemical carcinogen exposure; and drug-induced immunosuppression.
  • In patients with large, multifocal recurrent tumors, standard therapy with acceptable cosmetic outcomes may be difficult.
  • Photodynamic therapy (PDT) with photosensitizing agents selectively taken up by skin provides a primary or adjunct intraoperative option for treatment of this special group of cancer patients.
  • CONCLUSIONS: PHOTOFRIN-mediated PDT is an excellent locoregional oncological modality for aggressive primary or recurrent basal cell carcinoma and squamous cell carcinoma, particularly in elderly patients who were previously treated with extensive Mohs microsurgery, surgical resection, and external-beam radiation therapy.
  • Multiple repeat treatments are well tolerated, painless, without systemic morbidity, and amenable to local anesthesia or intravenous sedation for PDT alone, and wound healing and cosmetic outcomes are excellent.
  • [MeSH-major] Bowen's Disease / drug therapy. Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Hematoporphyrin Photoradiation. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Dihematoporphyrin Ether. Female. Humans. Male. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11404627.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


55. De Vos M, Leunen M, Fontaine C, De Sutter P: Successful Primary Treatment of a Hydatidiform Mole with Methotrexate and EMA/CO. Case Rep Med; 2009;2009:454161
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful Primary Treatment of a Hydatidiform Mole with Methotrexate and EMA/CO.
  • Background. The preferred treatment method of most hydatidiform moles is suction aspiration.
  • In rare circumstances uterine abnormalities may preclude surgical treatment. Case.
  • A 38-year-old woman with a complete hydatidiform mole and multiple uterine fibroids underwent a failed attempt at suction aspiration.
  • Following treatment with methotrexate, a nonmetastatic persistent trophoblastic tumour developed.
  • Conclusion. We propose that primary treatment of molar pregnancies with chemotherapy is a useful treatment option in cases where uterine abnormalities interfere with suction aspiration.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1996 Dec 5;335(23):1740-8 [8929267.001]
  • [Cites] Br J Obstet Gynaecol. 1994 Jul;101(7):637-8 [8043548.001]
  • [Cites] Am J Obstet Gynecol. 1988 Jun;158(6 Pt 1):1299-306 [3381858.001]
  • [Cites] Lancet Oncol. 2003 Nov;4(11):670-8 [14602247.001]
  • [Cites] Gynecol Oncol. 2000 Sep;78(3 Pt 1):309-12 [10985885.001]
  • (PMID = 19707478.001).
  • [ISSN] 1687-9627
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2729468
  •  go-up   go-down


56. Zavadil M, Feyereisl J, Safár P, Pán M: [Malignant trophoblastic tumors (MTT) treated in the years 1955-2004 in trophoblastic disease center in the Czech Republic (TDC-CZ): clinical-pathological features, curability, typing, pathogenesis]. Ceska Gynekol; 2004 Dec;69 Suppl 1:9-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The determination of curability of different histological types and risk stages (RS) used in TDC-CZ and a comparison with RS axccording to FIGO, WHO and NIH.
  • Differentiation of undifferentiated choriocarcinoma (CH-Und) alias Epitheloid Trophoblastic Tumor (ETT) from the given cohort of MIT and establishment of its clinical and biological properties, curability and formal pathogenesis.
  • RESULTS: Three hundred and seventy nine MTT cases were classified into 5 histological types onthe basis of analogy with developmental stages of 7 to 14 days old trophoblast.
  • 1: typical "classical" choriocarcinoma - No Special Type (CH-NST), which forms more than 80% of MTT.
  • Moreover, the degree of differentiation of tumorous trophoblast and its prevailing (cytological) type made it possible to define other 4 types, i.e.: 2: CH-syncytio-trophoblastic (CH-Syn), representing 3.8%; 3: CH-cytotrophoblastic CH-Cyt with 3.3%; 4: CH-dissociated (CH-Dis), representing 6%; 5: CH-undifferentiated (CH-Und) with 6.8%.
  • Mortality due to MIT of all mentioned types reached 94% until 1963, decreased to 43% until 1980 and has been 5.8% in the period of 1981-2004.
  • In the latter period of time (1981-2004), mortality due to CH-Cyt proved to be 40%, that due to CH-Dis being 11%, and CH-Und 18%, though.
  • Mortality of s.c.
  • The following outline includes only the main features: 1st RT includes CH-NST < 30mm limited to uterus in connection with mole.
  • 3rd RS according to FIGO is overestimated in view of 100% curability and the abc degree in 1st and 2nd RS are only of theoretical significance and irrelevant for the choice of treatment.
  • It is insidious for its seemingly primary extragenital symptomatology in seven out of 25 cases, low hCG values and poor sensitivity to chemotherapy. CONCLUSION:.
  • 1) The comparison of histological pictures of 379 MTT with developmental stages of orthologic trophoblast of 7-14 days old embryo was the basis for classification of 5 types of choriocarcinoma (CH): 1.
  • Differentiated CH "No Special Type" (CH-NST), 2.
  • 3) We have described biological properties of individual types of CH and established the way they influence curability.
  • 4) Four degrees of risk (RS) were specified in relation to 7 types of risk factors observed (1. size of tumor, 2. type of preceding pregnancy, 3. interval from pregnancy to the diagnosis, 4. histological type of CH, 5. number of metastases, 6. localization of metastases, 7. values of hCG).
  • The results proved to be similar, but in case of FIGO the 3rd degree was overestimated and the degrees abc in the 1st and 2nd RS were of theoretical importance only, therefore being of no values for the choice of treatment.
  • 7) It has been proved that the histological type of CH significantly influenced the determination of RS in the given patient.

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15748020.001).
  • [ISSN] 1210-7832
  • [Journal-full-title] Ceska gynekologie
  • [ISO-abbreviation] Ceska Gynekol
  • [Language] CZE
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


57. Scott JX, Krishnan S, Bourne AJ, Williams MP, Agzarian M, Revesz T: Treatment of metastatic sialoblastoma with chemotherapy and surgery. Pediatr Blood Cancer; 2008 Jan;50(1):134-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of metastatic sialoblastoma with chemotherapy and surgery.
  • We present a case of sialoblastoma with lung metastases that developed in a 4-year-old girl adjacent to a congenital nevus in the left cheek.
  • The patient responded well to chemotherapy and underwent surgical excision of the primary tumor, followed by three more courses of chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / secondary. Parotid Neoplasms / pathology. Pneumonectomy
  • [MeSH-minor] Child, Preschool. Facial Neoplasms / pathology. Female. Humans. Neoplasms, Multiple Primary / pathology. Nevus, Pigmented / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 16514617.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Altieri A, Franceschi S, Ferlay J, Smith J, La Vecchia C: Epidemiology and aetiology of gestational trophoblastic diseases. Lancet Oncol; 2003 Nov;4(11):670-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gestational trophoblastic diseases (GTD) consist of a group of neoplastic disorders arising from placental trophoblastic tissue after normal or abnormal fertilisation.
  • The WHO classification of GTD includes hydatidiform mole, invasive mole, choriocarcinoma, placental site trophoblastic tumour, and miscellaneous and unclassified trophoblastic lesions.
  • GTD have a varying potential for local invasion and metastases and they generally respond to chemotherapy.
  • Maternal age and a history of GTD have been established as strong risk factors for hydatidiform mole and choriocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14602247.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 73
  •  go-up   go-down


59. Sasaki S: The Japanese trophoblastic disease classification. J Reprod Med; 2004 Aug;49(8):637-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the clinical usefulness of the "diagnostic score"for the detection of choriocarcinoma in persistent gestational trophoblastic disease without histologic findings.
  • STUDY DESIGN: We reviewed the clinical records of and histologic reports on all 809 patients with persistent gestational trophoblastic disease treated with surgery and chemotherapy in Japan.
  • There were 347 cases of choriocarcinoma and 462 cases of invasive mole with histologic confirmation.
  • The specificity of the score (the true positive rate of the score for the histologic diagnosis of invasive mole) was 94.1%.
  • CONCLUSION: The diagnostic score is a unique scoring system for differentiating choriocarcinoma clinically from persistent gestational trophoblastic disease without histologic findings and for selecting the most appropriate chemotherapy.
  • The scoring system should be very useful for comparing the nearly true incidence and treatment results with choriocarcinoma between nations.
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Japan. Neoplasm Invasiveness. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15457854.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Garner E, Goldstein DP, Berkowitz RS, Wenzel L: Psychosocial and reproductive outcomes of gestational trophoblastic diseases. Best Pract Res Clin Obstet Gynaecol; 2003 Dec;17(6):959-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Current therapy for molar pregnancy and gestational trophoblastic neoplasias (GTNs) has resulted in high cure rates with preservation of fertility, even in the setting of chemotherapy for widespread metastatic disease.
  • Data from the New England Trophoblastic Disease Center on later pregnancies following complete and partial mole, as well as persistent GTN show that patients can, in general, anticipate normal subsequent pregnancy outcome.
  • Nevertheless, patients and their partners often express anxiety and fear related to the risk of disease recurrence and the outcome of subsequent pregnancies after treatment for gestational trophoblastic disease.
  • [MeSH-minor] Attitude to Health. Chorionic Gonadotropin / blood. Emotions. Female. Humans. Hydatidiform Mole / psychology. Male. Marriage. Pregnancy. Prognosis. Quality of Life. Recurrence. Stress, Psychological. Uterine Neoplasms / psychology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14614892.001).
  • [ISSN] 1521-6934
  • [Journal-full-title] Best practice & research. Clinical obstetrics & gynaecology
  • [ISO-abbreviation] Best Pract Res Clin Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin
  • [Number-of-references] 28
  •  go-up   go-down


61. Feng F, Xiang Y, Cao Y: Metastasis of gestational trophoblastic neoplasia to the spinal canal: a case report. J Reprod Med; 2009 Sep;54(9):576-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient received multiagent chemotherapy combined with intrathecal methotrexate administration.
  • Her neurologic symptoms improved remarkably after the cessation of chemotherapy.
  • CONCLUSION: Spinal canal metastasis of GTN is a possibility that must be considered in young women with a history of hydatidiform mole who have neurologic symptoms or signs, which were improved completely by chemotherapy alone in this case.
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Chorionic Gonadotropin, beta Subunit, Human / blood. Chorionic Gonadotropin, beta Subunit, Human / drug effects. Dactinomycin / administration & dosage. Etoposide / administration & dosage. Female. Floxuridine / administration & dosage. Humans. Magnetic Resonance Imaging. Methotrexate / administration & dosage. Pregnancy. Spinal Canal / pathology. Vincristine / administration & dosage. Young Adult

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19947036.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Chorionic Gonadotropin, beta Subunit, Human; 039LU44I5M / Floxuridine; 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


62. Matsui H, Iitsuka Y, Suzuka K, Yamazawa K, Tanaka N, Mitsuhashi A, Sekiya S: Early pregnancy outcomes after chemotherapy for gestational trophoblastic tumor. J Reprod Med; 2004 Jul;49(7):531-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early pregnancy outcomes after chemotherapy for gestational trophoblastic tumor.
  • OBJECTIVE: To analyze the outcome of the first pregnancy following chemotherapy for gestational trophoblastic tumor (GTT).
  • STUDY DESIGN: A total of 393 patients with GTT (87 with high-risk and 306 with low-risk GTT) underwent chemotherapy at Chiba University Hospital between 1974 and 2000.
  • Of them, 137 (19 with high-risk and 118 with low-risk GTT) who achieved primary remission and had at least 1 conception following chemotherapy were included in the study.
  • RESULTS: The overall outcomes of the first subsequent pregnancies in the 137 women treated with chemotherapy were comparable to those in the general Japanese population.
  • However, the incidence of abnormal pregnancies (spontaneous abortion, stillbirth, repeat mole) was significantly higher in women who conceived within 6 months of completing chemotherapy (6 of 16, 37.5%) than in those who conceived after the recommended waiting period, > 12 months (11 of 99, 10.5%) (P=.014).
  • CONCLUSION: Patients who achieved primary remission with various kinds of chemotherapy may anticipate a normal future reproductive outcome.
  • As pregnancies occurring within 6 months following remission are at risk of abnormality, a waiting period of at least 6 months after chemotherapy for GTT is recommended.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Gestational Trophoblastic Disease / drug therapy. Pregnancy Complications / chemically induced. Pregnancy Outcome. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Female. Humans. Pregnancy. Time Factors

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Health Problems in Pregnancy.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15305824.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


63. Winnepenninckx V, Van den Oord JJ: Gene expression profiling of primary cutaneous melanoma. Verh K Acad Geneeskd Belg; 2007;69(1):23-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling of primary cutaneous melanoma.
  • Cutaneous Malignant Melanoma (CMM) is the most malignant skin tumour in humans, the incidence of which is rising rapidly in most fair-skinned populations, without apparent decline in mortality.
  • The prognosis of patients with VGP melanoma depends on several clinical and histological parameters; the latter include thickness, mitotic activity, presence or absence of ulceration and regression, and pattern of lymphocytic host response.
  • To obtain insight in the molecular mechanisms of tumor progression in CMM, and in search of new prognostic markers, we performed global gene-expression profiling using 44K oligonucleotide micro-arrays on a unique retrospective series of 83 frozen primary MM with VGP, 9 metastases and 23 benign nevi.
  • Unsupervised analysis allowed us o identify clusters of melanoma patients with different outcome based on their gene expression profile only.
  • This signature was validated on a separate series of melanoma patients, and proved to have a predictive accuracy comparable to what can be obtained by tumour thickness and ulceration.
  • On an immunohistochemical level, we identified 8 new markers that may help in the prognostication of melanoma patients; three of these markers, i.e. the mini-chromosome maintenance (mcm) proteins mcm3, 4 and 6, hat are involved in DNA-replication, had independent prognostic value.
  • CMM is notorious for its resistance to chemotherapy, and disseminated CMM is a uniformly fatal disease.
  • As several of the progression-related genes, encode molecules that have been the target of established or xperimental cancer therapies, our results may hopefully contribute to the treatment of end-stage CMM-patients.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Melanoma / genetics. Skin Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17427873.001).
  • [ISSN] 0302-6469
  • [Journal-full-title] Verhandelingen - Koninklijke Academie voor Geneeskunde van België
  • [ISO-abbreviation] Verh. K. Acad. Geneeskd. Belg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Belgium
  • [Number-of-references] 54
  •  go-up   go-down


64. Zacharowski K, Blackburn B, Thiemermann C: Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. Eur J Pharmacol; 2001 Apr 20;418(1-2):105-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This metabolic switch increases ATP production per mole of oxygen consumed, reduces the rise in lactic acid and acidosis, and maintains myocardial function under conditions of reduced myocardial oxygen delivery.
  • This study demonstrates for the first time that ranolazine significantly reduces (i) infarct size and (ii) cardiac troponin T release in rats subjected to left anterior descending coronary artery occlusion-reperfusion.
  • [MeSH-minor] Acetanilides. Animals. Blood Pressure / drug effects. Coronary Disease / drug therapy. Coronary Disease / metabolism. Coronary Disease / pathology. Coronary Vessels / physiopathology. Disease Models, Animal. Heart Rate / drug effects. Male. Myocardial Reperfusion. Oxidation-Reduction / drug effects. Ranolazine. Rats. Rats, Wistar

  • MedlinePlus Health Information. consumer health - Heart Attack.
  • Hazardous Substances Data Bank. Ranolazine .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11334871.001).
  • [ISSN] 0014-2999
  • [Journal-full-title] European journal of pharmacology
  • [ISO-abbreviation] Eur. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Acetanilides; 0 / Fatty Acids; 0 / Piperazines; 0 / Troponin T; A6IEZ5M406 / Ranolazine
  •  go-up   go-down


65. Meyer S, Vogt T, Landthaler M, Berand A, Reichle A, Bataille F, Marx AH, Menz A, Hartmann A, Kunz-Schughart LA, Wild PJ: Cyclooxygenase 2 (COX2) and Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Are Stage-Dependent Prognostic Markers of Malignant Melanoma. PPAR Res; 2009;2009:848645
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclooxygenase 2 (COX2) and Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Are Stage-Dependent Prognostic Markers of Malignant Melanoma.
  • Using tissue microarrays (TMAs) we studied COX2/PPARG immunoreactivity in a broad spectrum of tumors focussing on clinicopathological correlations and the outcome of patients with malignant melanoma (MM).
  • TMA-1 contained normal and tumor tissues (n = 3448) from 47 organs including skin neoplasms (n = 323); TMA-2 88 primary MM, 101 metastases, and 161 benign nevi.
  • Based on a biomodulatory approach combining COX/PPAR-targeting with metronomic low-dose chemotherapy metastases of 36 patients participating in a randomized trial with metastatic (stage IV) melanoma were investigated using TMA-3.
  • COX2/PPARG immunoreactivity significantly increased from nevi to primary MM and metastases; COX2 positivity was associated with advanced Clark levels and shorter recurrence-free survival.
  • Patients with PPARG-positive metastases and biomodulatory metronomic chemotherapy alone or combined with COX2/PPARG-targeting showed a significantly prolonged progression-free survival.
  • In metastatic MM, PPARG expression may be a predicitive marker for response to biomodulatory stroma-targeted therapy.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell. 1998 Feb;1(3):465-70 [9660931.001]
  • [Cites] Clin Nephrol. 1999 Feb;51(2):67-72 [10069640.001]
  • [Cites] Br J Cancer. 2005 Jan 17;92(1):113-9 [15583697.001]
  • [Cites] J Cutan Pathol. 2005 May;32(5):340-7 [15811118.001]
  • [Cites] Curr Cancer Drug Targets. 2005 Sep;5(6):393-419 [16178816.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Feb;132(2):76-84 [16215757.001]
  • [Cites] Anticancer Drugs. 2006 Mar;17(3):325-32 [16520661.001]
  • [Cites] Arch Dermatol. 2006 Apr;142(4):471-6 [16618867.001]
  • [Cites] J Clin Pathol. 2007 Mar;60(3):307-10 [16698954.001]
  • [Cites] Melanoma Res. 2007 Dec;17(6):360-4 [17992118.001]
  • [Cites] J Cutan Pathol. 2008 Nov;35(11):989-94 [18537861.001]
  • [Cites] J Clin Invest. 2000 Apr;105(8):1045-7 [10772648.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):303-8 [11196178.001]
  • [Cites] J Biol Chem. 2000 Sep 8;275(36):28028-32 [10827178.001]
  • [Cites] J Natl Cancer Inst. 2001 Aug 1;93(15):1141-6 [11481385.001]
  • [Cites] J Pathol. 2001 Jul;194(3):349-57 [11439368.001]
  • [Cites] Exp Cell Res. 2001 Jul 1;267(1):73-80 [11412039.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1733-40 [11245490.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10990-5 [10984506.001]
  • [Cites] J Pathol. 2001 Sep;195(1):72-9 [11568893.001]
  • [Cites] Ann N Y Acad Sci. 2001 Dec;952:109-15 [11795429.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):1-9 [12538445.001]
  • [Cites] Melanoma Res. 2003 Oct;13(5):447-56 [14512786.001]
  • [Cites] Novartis Found Symp. 2004;256:6-21; discussion 22-8, 49-52, 266-9 [15027481.001]
  • [Cites] Lancet Oncol. 2004 Jul;5(7):419-29 [15231248.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7384-8 [1380156.001]
  • [Cites] Carcinogenesis. 1998 Jan;19(1):49-53 [9472692.001]
  • [Cites] Carcinogenesis. 1998 May;19(5):723-9 [9635856.001]
  • [Cites] Cancer. 2004 Nov 15;101(10):2247-56 [15470711.001]
  • (PMID = 19639032.001).
  • [ISSN] 1687-4757
  • [Journal-full-title] PPAR research
  • [ISO-abbreviation] PPAR Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2712952
  •  go-up   go-down


66. Lara FM, Alvarado AM, Candelaria M, Arce CS: [Gestational trophoblastic disease. Experience at National Institute of Cancerology]. Ginecol Obstet Mex; 2005 Jun;73(6):308-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Gestational trophoblastic disease represents a variety of conditions that include hydatiform mole and choriocarcinoma.
  • PATIENTS AND METHODS: This is a retrospective and descriptive analysis of patients with partial, complete or persistent hydatiform mole or choriocarcinoma diagnosis made from January 1988 to December 2003.
  • We studied demographic characteristics, risk groups, treatment and response.
  • Thirty patients had low risk disease and 25 of them received chemotherapy based in methotrexate and folinic acid, 88% had complete response.
  • In 10% of the cases the use of salvage chemotherapy showed a complete response.
  • Forty-one cases belonging to intermediate and high risk group were treated with chemotherapy (etoposide and actinomycin D in 68.3%).
  • Two cases developed second malignancies secondary to etoposide.
  • Etoposide and actynomicine D as first line chemotherapy had comparable results to those reported with EMA-CO and MAC.

  • Genetic Alliance. consumer health - Gestational Trophoblastic Disease.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16309037.001).
  • [ISSN] 0300-9041
  • [Journal-full-title] Ginecología y obstetricia de México
  • [ISO-abbreviation] Ginecol Obstet Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


67. Lommatzsch PK, Werschnik C: [Malignant conjunctival melanoma. Clinical review with recommendations for diagnosis, therapy and follow-up]. Klin Monbl Augenheilkd; 2002 Oct;219(10):710-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant conjunctival melanoma. Clinical review with recommendations for diagnosis, therapy and follow-up].
  • [Transliterated title] Das maligne Melanom der Bindehaut - Klinische Ubersicht mit Empfehlungen zur Diagnose, Therapie und Nachsorge.
  • BACKGROUND: Malignant conjunctival melanoma is a rare disease with an incidence of 0.03 - 0.08.
  • This tumour is potentially lethal, even after prompt and proper treatment, especially after delayed onset of therapy.
  • Conjunctival melanoma arises from primary acquired melanosis (PAM), from a preexisting nevus or "de novo" without any precursor at all.
  • In contrast to uveal melanomas, conjunctival melanoma metastasizes via the ipsilateral lymph nodes and in rare cases through the lacrimal duct into the nasal cavities.
  • RESULTS: Removing the local tumour with preservation of visual functions and avoidance of metastases is the therapy of choice.
  • To minimize local recurrence rate surgical excision should be combined with an additional procedure such as cryotherapy, irradiation, or local chemotherapy with MMC.
  • In our own patients the 5-year, 10-year, and 15-year cumulative melanoma-specific survival rate was 84.4 %, 77.7 %, and 75.0 %, respectively.
  • Up to now there is no effective treatment of the metastatic disease.
  • CONCLUSION: In all cases with pigmented lesions of the conjunctiva exclusion of a malignant melanoma has to be the first aim.
  • A patient suffering from a conjunctival melanoma should be referred to an ophthalmo-oncological center for proper treatment.
  • An international prospective study would be worthwhile to answer open questions and to develop new kinds of treatment of this potentially fatal tumour.
  • [MeSH-major] Conjunctival Neoplasms / diagnosis. Melanoma / diagnosis
  • [MeSH-minor] Combined Modality Therapy. Conjunctiva / pathology. Humans. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12447715.001).
  • [ISSN] 0023-2165
  • [Journal-full-title] Klinische Monatsblätter für Augenheilkunde
  • [ISO-abbreviation] Klin Monbl Augenheilkd
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 45
  •  go-up   go-down


68. Lin SM, Ferrucci S: Primary acquired melanosis of the conjunctiva. Optometry; 2006 May;77(5):223-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The presence or absence of atypia is helpful in determining the potential for malignancy, because PAM without atypia is usually benign, whereas PAM with atypia may convert into a conjunctival melanoma.
  • His ocular history was remarkable for early cataracts and for a choroidal nevus.
  • The patient was subsequently treated with topical 5-fluorouracil chemotherapy.
  • There have been no signs of recurrence to date after his treatment.
  • If atypia is present, treatment options include local excision, cryotherapy, and topical chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16651212.001).
  • [ISSN] 1529-1839
  • [Journal-full-title] Optometry (St. Louis, Mo.)
  • [ISO-abbreviation] Optometry
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Toth B, Roth K, Kunert-Keil C, Scholz C, Schulze S, Mylonas I, Friese K, Jeschke U: Glycodelin protein and mRNA is downregulated in human first trimester abortion and partially upregulated in mole pregnancy. J Histochem Cytochem; 2008 May;56(5):477-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glycodelin protein and mRNA is downregulated in human first trimester abortion and partially upregulated in mole pregnancy.
  • We evaluated the expression of Gd protein and mRNA in first trimester decidual tissue of normal pregnancies and spontaneous abortion and hydatidiform moles.
  • In decidual tissue of abortion patients, Gd expression was significantly decreased compared with normal gestation, which was confirmed by in situ hybridization.
  • In mole pregnancy, an upregulation of Gd in the first 8 weeks of pregnancy was present.
  • Gd is a main product of decidual tissue in the first trimester of human pregnancy.
  • Therefore, we speculate that hCG could be one of the factors regulating Gd expression because hCG is downregulated in women with abortion and upregulated in mole pregnancy.
  • [MeSH-major] Abortion, Spontaneous / genetics. Down-Regulation. Gene Expression Regulation, Neoplastic. Glycoproteins / genetics. Hydatidiform Mole / genetics. Pregnancy Proteins / genetics. Pregnancy Trimester, First / genetics. Up-Regulation

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Miscarriage.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Biotechnol. 2000 Jan;14(1):47-57 [10911614.001]
  • [Cites] Hum Reprod Update. 2007 Nov-Dec;13(6):581-90 [17626114.001]
  • [Cites] Mol Hum Reprod. 2002 Feb;8(2):142-8 [11818517.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2003 Jun 10;108(2):199-202 [12781411.001]
  • [Cites] Histochem Cell Biol. 2003 May;119(5):345-54 [12743827.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2A):1107-13 [12820356.001]
  • [Cites] Arch Gynecol Obstet. 2003 Aug;268(3):162-7 [12942243.001]
  • [Cites] Biol Reprod. 2003 Nov;69(5):1545-51 [12826581.001]
  • [Cites] Int J Gynaecol Obstet. 2004 May;85(2):105-18 [15099771.001]
  • [Cites] J Clin Endocrinol Metab. 1981 May;52(5):1006-8 [7014586.001]
  • [Cites] Biol Reprod. 1981 Oct;25(3):591-8 [6796144.001]
  • [Cites] Br J Obstet Gynaecol. 1985 Nov;92(11):1145-51 [4063232.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1986;409(2):127-47 [2424168.001]
  • [Cites] Am J Reprod Immunol. 1991 Dec;26(4):137-42 [1840727.001]
  • [Cites] Fertil Steril. 1993 Jan;59(1):187-91 [8419206.001]
  • [Cites] Hum Reprod. 1993 Jun;8(6):793-8 [8345065.001]
  • [Cites] Glycobiology. 1994 Apr;4(2):221-5 [7519910.001]
  • [Cites] Hum Reprod. 1994 Jul;9(7):1339-43 [7962445.001]
  • [Cites] J Biol Chem. 1995 Oct 13;270(41):24116-26 [7592613.001]
  • [Cites] Arch Gynecol Obstet. 1996;258(4):165-9 [8844133.001]
  • [Cites] J Biol Chem. 1996 Dec 13;271(50):32159-67 [8943270.001]
  • [Cites] FEBS Lett. 1998 Oct 9;436(3):455-60 [9801168.001]
  • [Cites] Cell Immunol. 1999 Jan 10;191(1):26-33 [9918684.001]
  • [Cites] J Mol Endocrinol. 1999 Aug;23(1):57-66 [10425447.001]
  • [Cites] J Perinat Med. 2005;33(3):212-8 [15914343.001]
  • [Cites] Arch Gynecol Obstet. 2005 Jul;272(2):151-9 [15549334.001]
  • [Cites] Fertil Steril. 2006 Nov;86(5):1488-97 [17070198.001]
  • [Cites] J Biol Chem. 2007 Feb 23;282(8):5378-88 [17192260.001]
  • [Cites] Blood. 2001 Dec 15;98(13):3727-32 [11739178.001]
  • (PMID = 18256018.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Chorionic Gonadotropin; 0 / Glycoproteins; 0 / PAEP protein, human; 0 / Pregnancy Proteins; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2324189
  •  go-up   go-down


70. Yaldizli O, Baumberger P, Putzki N: [Natalizumab and atypical naevi: Comments on the pharmacovigilance note by J.-L. Schmutz et al]. Ann Dermatol Venereol; 2009 May;136(5):450-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Natalizumab et naevus atypiques: commentaires sur la note de pharmacovigilance de J.-L. Schmutz et al.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Nevus / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Humans. Melanoma / drug therapy. Natalizumab. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Moles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Ann Dermatol Venereol. 2008 Oct;135(10):725-6 [18929933.001]
  • (PMID = 19442806.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Comment; Letter
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Natalizumab
  •  go-up   go-down


71. Costa HL, Doyle P: Influence of oral contraceptives in the development of post-molar trophoblastic neoplasia--a systematic review. Gynecol Oncol; 2006 Mar;100(3):579-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Controversy exists regarding the use of oral contraceptives following hydatidiform mole and possible increased risk of persistent trophoblastic neoplasia.
  • The purpose of this study is to perform a systematic review of the literature to assess the evidence for and against a possible link between oral contraceptive use and the need for chemotherapy after molar evacuation.
  • We collected or calculated risk ratios for the incidence of gestational trophoblastic neoplasia and hCG regression time associated with oral contraceptive use.
  • [MeSH-minor] Chorionic Gonadotropin, beta Subunit, Human / blood. Combined Modality Therapy. Female. Humans. Hydatidiform Mole / drug therapy. Hydatidiform Mole / surgery. Pregnancy. Randomized Controlled Trials as Topic

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16297971.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / Contraceptives, Oral
  • [Number-of-references] 27
  •  go-up   go-down


72. Kulik DA, Kersten M: Aqueous solubility diagrams for cementitious waste stabilization systems. 4. A carbonation model for Zn-doped calcium silicate hydrate by Gibbs energy minimization. Environ Sci Technol; 2002 Jul 1;36(13):2926-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both the stoichiometry and standard molar Gibbs energy (G(o)298) of the Zn-bearing end-member in the ideal ternary Zn-bearing calcium silicate hydrate (CZSH) solid solution were determined by a "dual-thermodynamic" (GEM-DT) estimation technique.
  • The model results predict that at low to moderate Zn loading (< or = 1% per mole Si), CZSH-type compounds can efficiently immobilize Zn in the near field of a cement-stabilized waste repository.

  • Hazardous Substances Data Bank. CALCIUM COMPOUNDS .
  • Hazardous Substances Data Bank. Calcium silicate .
  • Hazardous Substances Data Bank. WOLLASTONITE .
  • Hazardous Substances Data Bank. ZINC, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12144269.001).
  • [ISSN] 0013-936X
  • [Journal-full-title] Environmental science & technology
  • [ISO-abbreviation] Environ. Sci. Technol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium Compounds; 0 / Silicates; J41CSQ7QDS / Zinc; S4255P4G5M / calcium silicate
  •  go-up   go-down


73. Holmes G, Wines N, Ryman W: Giant congenital melanocytic naevus and symptomatic thoracic arachnoid cyst. Australas J Dermatol; 2001 May;42(2):124-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant congenital melanocytic naevus and symptomatic thoracic arachnoid cyst.
  • This case highlights the need to consider that the management of patients with giant congenital melanocytic naevus is variable depending on the age of the patient, the location of lesions and the presence of complications such as neurocutaneous melanosis.
  • [MeSH-major] Arachnoid Cysts / complications. Arachnoid Cysts / diagnosis. Nevus, Pigmented / complications. Skin Neoplasms / complications. Spinal Cord Diseases / complications. Spinal Cord Diseases / diagnosis
  • [MeSH-minor] Adult. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Severity of Illness Index. Thoracic Vertebrae

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Spinal Cord Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11309037.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


74. Tran MA, Gowda R, Sharma A, Park EJ, Adair J, Kester M, Smith NB, Robertson GP: Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development. Cancer Res; 2008 Sep 15;68(18):7638-49
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development.
  • Most events promoting early melanoma development are yet to be identified, but deregulation of the B-Raf and Akt3 signaling cascades is an important regulator of this process.
  • Approximately 90% of normal moles and approximately 60% of early invasive cutaneous melanomas contain a T1799A B-Raf mutation ((V600E)B-Raf), leading to 10 times higher enzyme activity and constitutive activation of the mitogen-activated protein kinase pathway.
  • Therefore, targeting (V600E)B-Raf and Akt3 signaling is necessary to prevent or treat cutaneous melanocytic lesions.
  • In this study, a unique nanoliposomal-ultrasound-mediated approach has been developed for delivering small interfering RNA (siRNA) specifically targeting (V600E)B-Raf and Akt3 into melanocytic tumors present in skin to retard melanoma development.
  • Novel cationic nanoliposomes stably encapsulate siRNA targeting (V600E)B-Raf or Akt3, providing protection from degradation and facilitating entry into melanoma cells to decrease expression of these proteins.
  • Low-frequency ultrasound using a lightweight four-cymbal transducer array enables penetration of nanoliposomal-siRNA complex throughout the epidermal and dermal layers of laboratory-generated or animal skin.
  • Nanoliposomal-mediated siRNA targeting of (V600E)B-Raf and Akt3 led to a cooperatively acting approximately 65% decrease in early or invasive cutaneous melanoma compared with inhibition of each singly with negligible associated systemic toxicity.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1998 Jun;77(12):2336-42 [9649155.001]
  • [Cites] Methods Enzymol. 2005;392:112-24 [15644178.001]
  • [Cites] Int J Oncol. 2005 Apr;26(4):1087-91 [15754006.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2412-21 [15781657.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3465-74 [15867249.001]
  • [Cites] Pharmacol Ther. 2005 Aug;107(2):222-39 [15908010.001]
  • [Cites] Oncogene. 2005 Sep 15;24(41):6292-302 [16007203.001]
  • [Cites] Mol Ther. 2006 Apr;13(4):644-70 [16481219.001]
  • [Cites] J Pharm Pharmacol. 2006 Apr;58(4):415-29 [16597359.001]
  • [Cites] J Control Release. 2006 May 15;112(2):229-39 [16545478.001]
  • [Cites] Mol Cancer Ther. 2006 May;5(5):1136-44 [16731745.001]
  • [Cites] Yonsei Med J. 2006 Jun 30;47(3):293-306 [16807977.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):8200-9 [16912199.001]
  • [Cites] Clin Cancer Res. 2006 Aug 15;12(16):4916-24 [16914580.001]
  • [Cites] Mol Cancer Ther. 2006 Dec;5(12):3071-7 [17172409.001]
  • [Cites] Nat Rev Genet. 2007 Mar;8(3):173-84 [17304245.001]
  • [Cites] Melanoma Res. 2007 Apr;17(2):117-27 [17496787.001]
  • [Cites] Pharm Res. 2007 Jul;24(7):1396-401 [17443398.001]
  • [Cites] Bioconjug Chem. 2007 Sep-Oct;18(5):1391-6 [17630789.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3429-39 [18451171.001]
  • [Cites] Oncology (Williston Park). 2001 May;15(5 Suppl 7):44-8 [11396365.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Cancer Biol Ther. 2002 Jan-Feb;1(1):14-7 [12170758.001]
  • [Cites] IEEE Trans Ultrason Ferroelectr Freq Control. 2002 Oct;49(10):1430-6 [12403144.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6997-7000 [12460918.001]
  • [Cites] J Mol Biol. 2003 Apr 4;327(4):761-6 [12654261.001]
  • [Cites] Ultrasound Med Biol. 2003 Feb;29(2):311-7 [12659919.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2881-90 [12782594.001]
  • [Cites] Ultrasound Med Biol. 2003 Aug;29(8):1205-10 [12946523.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5198-202 [14500344.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Nov;307(2):468-75 [12975495.001]
  • [Cites] Br J Cancer. 2003 Nov 3;89(9):1620-6 [14583759.001]
  • [Cites] J Invest Dermatol. 2003 Nov;121(5):1160-2 [14708620.001]
  • [Cites] FEBS Lett. 2004 Jan 30;558(1-3):63-8 [14759517.001]
  • [Cites] IEEE Trans Ultrason Ferroelectr Freq Control. 2004 Feb;51(2):176-80 [15055807.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2552-60 [15059911.001]
  • [Cites] Methods. 2004 Jun;33(2):151-63 [15121170.001]
  • [Cites] Int J Dermatol. 2004 Jul;43(7):538-47 [15230899.001]
  • [Cites] Drug Discov Today. 2004 Aug 1;9(15):670-6 [15279850.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7002-10 [15466193.001]
  • [Cites] J Invest Dermatol. 2004 Nov;123(5):990-2 [15482489.001]
  • [Cites] Adv Enzyme Regul. 1984;22:27-55 [6382953.001]
  • [Cites] Cancer Commun. 1991 Jul;3(7):207-12 [1867954.001]
  • [Cites] Cancer Res. 1994 Feb 15;54(4):987-92 [8313389.001]
  • [Cites] Melanoma Res. 1997 Aug;7 Suppl 2:S35-42 [9578415.001]
  • (PMID = 18794153.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA119309-01A1; United States / NCI NIH HHS / CA / R03 CA119309-01A1; United States / NCI NIH HHS / CA / 1-R03-CA128033-01; United States / NCI NIH HHS / CA / R03 CA119309; United States / NCI NIH HHS / CA / R03 CA128033
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Liposomes; 0 / RNA, Small Interfering; EC 2.7.1.- / AKT3 protein, human; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  • [Other-IDs] NLM/ NIHMS456582; NLM/ PMC3628540
  •  go-up   go-down


75. Growdon WB, Wolfberg AJ, Goldstein DP, Feltmate CM, Chinchilla ME, Lieberman ES, Berkowitz RS: Low-risk gestational trophoblastic neoplasia and methotrexate resistance: predictors of response to treatment with actinomycin D and need for combination chemotherapy. J Reprod Med; 2010 Jul-Aug;55(7-8):279-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-risk gestational trophoblastic neoplasia and methotrexate resistance: predictors of response to treatment with actinomycin D and need for combination chemotherapy.
  • OBJECTIVE: To determine whether any clinical parameters predict the need for multiagent chemotherapy for treatment of low-risk gestational trophoblastic neoplasia (GTN) after the development of methotrexate (MTX) resistance.
  • RESULTS: We analyzed data from 150 women (40 with partial mole, 110 with complete mole) who received single-agent MTX for low-risk GTN using FIGO and WHO scoring systems.
  • Of the 45 women who developed MTX resistance, the majority (37/45) of these patients received actinomycin D, with 10 patients ultimately requiring multiagent chemotherapy.
  • The requirement for multiagent chemotherapy following MTX resistance was associated with a beta-hCG > 600 mlU/mL 1 week following initial MTX therapy (p < 0.03).
  • Conversely, a beta-hCG < 600 mlU/mL 1 week following initial MTX therapy was as-sociated with a 93% probability of remission with actinomycin D alone.
  • CONCLUSION: The prognosis for patients with low-risk GTN following molar gestation is excellent, with 100% remission rate, though a small but significant proportion (7%) required multiagent chemotherapy.
  • The need for multiagent chemotherapy was associated with beta-hCG levels 1 week following initial MTX therapy.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Neoplasm. Gestational Trophoblastic Disease / drug therapy. Methotrexate / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Chorionic Gonadotropin, beta Subunit, Human / blood. Cyclophosphamide / therapeutic use. Dactinomycin / administration & dosage. Dactinomycin / therapeutic use. Etoposide / administration & dosage. Female. Humans. Middle Aged. Pregnancy. Registries. Remission Induction. Retrospective Studies. Uterine Neoplasms / drug therapy. Uterine Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20795339.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Chorionic Gonadotropin, beta Subunit, Human; 1CC1JFE158 / Dactinomycin; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate; MAC combination
  •  go-up   go-down


76. Takahashi Y, Murota H, Tarutani M, Sano S, Okinaga T, Tominaga K, Yano T, Katayama I: A case of juvenile dermatomyositis manifesting inflammatory epidermal nevus-like skin lesions: unrecognized cutaneous manifestation of blaschkitis? Allergol Int; 2010 Dec;59(4):425-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of juvenile dermatomyositis manifesting inflammatory epidermal nevus-like skin lesions: unrecognized cutaneous manifestation of blaschkitis?
  • BACKGROUND: Juvenile dermatomyositis is potentially life threatening rare autoimmune illness that mainly affects muscle and skin.
  • CASE SUMMARY: We report an 8-year-old male juvenile dermatomyositis who presented epidermal nevus like-lesions on the back of the right thigh.
  • However, epidermal nevus-like skin lesions, an acquired inflammatory dermatosis that follows Blaschko lines, seen in this case have been rarely reported in the literatures.
  • [MeSH-major] Muscle Tonus / immunology. Muscle, Skeletal / pathology. Skin / pathology
  • [MeSH-minor] Biopsy. Child. Child, Preschool. Dermatomyositis / diagnosis. Dermatomyositis / drug therapy. Dermatomyositis / pathology. Dermatomyositis / physiopathology. Erythema. Humans. Immunoglobulin E / blood. Inflammation. Keratoderma, Palmoplantar. Male. Nevus, Sebaceous of Jadassohn. Prednisolone / therapeutic use

  • Genetic Alliance. consumer health - Dermatomyositis.
  • Genetic Alliance. consumer health - Juvenile dermatomyositis.
  • Genetic Alliance. consumer health - Nevus.
  • Genetic Alliance. consumer health - Epidermal nevus.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Allergol Int. 2011 Sep;60(3):401 [21502807.001]
  • (PMID = 20962570.001).
  • [ISSN] 1440-1592
  • [Journal-full-title] Allergology international : official journal of the Japanese Society of Allergology
  • [ISO-abbreviation] Allergol Int
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 37341-29-0 / Immunoglobulin E; 9PHQ9Y1OLM / Prednisolone; Amyopathic dermatomyositis
  •  go-up   go-down


77. Mudry B, Guy RH, Begoña Delgado-Charro M: Prediction of iontophoretic transport across the skin. J Control Release; 2006 Apr 10;111(3):362-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prediction of iontophoretic transport across the skin.
  • The objective of this work was to demonstrate that the efficiency of iontophoretic transport across the skin (which is measured in terms of an ion's transport number), either for drug delivery or for therapeutic drug monitoring, depends implicitly on the molar fraction of the species of interest over a wide range of experimental conditions both in vitro and in vivo.
  • Three sets of data from the literature were assessed to establish the direct relationship between transport number and mole fraction.
  • Not only does this validate an in vitro model typically used in iontophoresis research, it also demonstrates the potential of this approach to predict the feasibility of iontophoretic transport across the skin.
  • [MeSH-major] Antimanic Agents / metabolism. Iontophoresis / methods. Lithium Compounds / metabolism. Skin Absorption
  • [MeSH-minor] Biological Transport. Bipolar Disorder / drug therapy. Bipolar Disorder / metabolism. Cations. Drug Monitoring. Humans. Reproducibility of Results

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LITHIUM COMPOUNDS .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16488047.001).
  • [ISSN] 0168-3659
  • [Journal-full-title] Journal of controlled release : official journal of the Controlled Release Society
  • [ISO-abbreviation] J Control Release
  • [Language] eng
  • [Grant] United States / NIBIB NIH HHS / EB / EB 001420
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antimanic Agents; 0 / Cations; 0 / Lithium Compounds
  •  go-up   go-down


78. Todea V, Stan C, David C, Kauksar E, Călugăru M: [Trigeminal neuropathy, diagnostic and treatment problems]. Oftalmologia; 2002;55(4):34-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Trigeminal neuropathy, diagnostic and treatment problems].
  • AIM OF THE STUDY: Clinical evaluation of patients with the diagnosis of Sturge-Weber syndrome (encephalotrigeminal angiomathosis) for establishing an accurate diagnosis and therapy.
  • RESULTS: The analysis of our cases showed that glaucoma does not correlate with the extension of skin lesion (nevus flammeus).
  • The outcome of glaucoma's therapy is dictated by the adjustment of the therapy to the type of glaucoma.
  • CONCLUSION: Glaucoma associated with the Sturge-Weber syndrome has always proved to be a therapeutic challenge and remains one of the causes of increased intraocular pressure, difficult to control.
  • The management of glaucoma in Sturge-Weber syndrome includes surgical and drug therapy.

  • MedlinePlus Health Information. consumer health - Glaucoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12723175.001).
  • [ISSN] 1220-0875
  • [Journal-full-title] Oftalmologia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Oftalmologia
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


79. Cui JQ, Shi YF, Zhou HJ: [Expression of R2 protein in gestational trophoblastic diseases]. Zhejiang Da Xue Xue Bao Yi Xue Ban; 2004 Sep;33(5):433-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The expression of R2 was detected with immunohistochemical method in 15 cases of normal villi, 38 cases of hydatidiform mole (HM), 42 cases of invasive moles (IM) and 18 cases of choriocarcinoma (CC).
  • Among 38 cases of HM, R2 expression in 8 cases with malignant transformation was significantly higher than in 30 cases of non-malignant transformation mole (P=0.02).
  • Preoperative chemotherapy of gestational trophoblastic tumor including IM and CC did not influence the R2 expression.
  • CONCLUSION: R2 expression in GTD is increased, which may be associated with the hyperplasia of trophoblasts, malignant transformation of hydatidiform mole and drug resistance of trophoblastic tumor.

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15476328.001).
  • [ISSN] 1008-9292
  • [Journal-full-title] Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences
  • [ISO-abbreviation] Zhejiang Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 1.17.4.- / Ribonucleotide Reductases; EC 1.17.4.- / ribonucleotide reductase R2 subunit
  •  go-up   go-down


80. Kim JJ, Chang MW, Shwayder T: Topical tretinoin and 5-fluorouracil in the treatment of linear verrucous epidermal nevus. J Am Acad Dermatol; 2000 Jul;43(1 Pt 1):129-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical tretinoin and 5-fluorouracil in the treatment of linear verrucous epidermal nevus.
  • Treatment of a linear verrucous epidermal nevus using topical 0.1% tretinoin cream and 5% 5-fluorouracil in a young patient is described.
  • In 1994, successful topical therapy using this combination was described in the management of an inflammatory linear verrucous epidermal nevus.
  • We report another case in which treatment of a noninflamed epidermal verrucous nevus with 0.1% tretinoin and 5% 5-fluorouracil resulted in significant improvement.
  • An updated summary of the literature discussing management of epidermal nevi is presented.
  • [MeSH-major] Antimetabolites / therapeutic use. Fluorouracil / therapeutic use. Hamartoma / drug therapy. Keratolytic Agents / therapeutic use. Skin Diseases / drug therapy. Tretinoin / therapeutic use
  • [MeSH-minor] Child. Drug Combinations. Humans. Male

  • Genetic Alliance. consumer health - Nevus.
  • Genetic Alliance. consumer health - Verrucous nevus.
  • Genetic Alliance. consumer health - Epidermal nevus.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10863239.001).
  • [ISSN] 0190-9622
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antimetabolites; 0 / Drug Combinations; 0 / Keratolytic Agents; 5688UTC01R / Tretinoin; U3P01618RT / Fluorouracil
  •  go-up   go-down


81. Jain KA: Gestational trophoblastic disease: pictorial review. Ultrasound Q; 2005 Dec;21(4):245-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Partial or complete hydatidiform moles can be diagnosed in early gestation.
  • Sonography and Doppler imaging are helpful in diagnosing gestational trophoblastic disease, in determining whether invasive disease is present, in detecting recurrent disease, and in following the effectiveness of chemotherapy.
  • [MeSH-minor] Adult. Choriocarcinoma / physiopathology. Choriocarcinoma / ultrasonography. Education, Medical, Continuing. Female. Humans. Hydatidiform Mole / physiopathology. Hydatidiform Mole / ultrasonography. Middle Aged. Neoplasm Staging. Pregnancy. Sensitivity and Specificity. Severity of Illness Index


82. Horn LC, Kowalzik J, Bilek K, Richter CE, Einenkel J: Prognostic value of trophoblastic proliferation in complete hydatidiform moles in predicting persistent disease. Pathol Res Pract; 2006;202(3):151-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of trophoblastic proliferation in complete hydatidiform moles in predicting persistent disease.
  • The clinical outcome of patients with complete hydatidiform moles (CHM) is variable.
  • The need for chemotherapy and occurrence of metastatic disease was correlated with the histologic grade using a three-level score.
  • Twelve out of 151 cases were re-evaluated as hydropic abortion, partial moles, or were insufficient for morphologic examination, representing a diagnostic agreement of 92%.
  • Twenty-six of the CHM (19%) required chemotherapy.
  • Grade 3, on histology, showed a positive correlation with the necessity of chemotherapy (p=0.04), but not with the occurrence of metastatic disease.
  • [MeSH-major] Hydatidiform Mole / diagnosis. Trophoblasts / pathology
  • [MeSH-minor] Adolescent. Adult. Cell Proliferation. Chorionic Gonadotropin / metabolism. Diagnosis, Differential. Disease Progression. Female. Humans. Middle Aged. Neoplasm Metastasis / pathology. Pregnancy. Prognosis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16436315.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin
  •  go-up   go-down


83. Chapman K: Cervical pregnancy with hydatidiform mole. Acta Obstet Gynecol Scand; 2001 Jul;80(7):657-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical pregnancy with hydatidiform mole.
  • [MeSH-major] Hydatidiform Mole / complications. Pregnancy, Ectopic / complications. Uterine Neoplasms / complications
  • [MeSH-minor] Adult. Cervix Uteri / surgery. Cervix Uteri / ultrasonography. Endometriosis / complications. Endometriosis / drug therapy. Female. Humans. Pregnancy. Pregnancy Outcome


84. Khaitan D, Chandna S, Arya MB, Dwarakanath BS: Differential mechanisms of radiosensitization by 2-deoxy-D-glucose in the monolayers and multicellular spheroids of a human glioma cell line. Cancer Biol Ther; 2006 Sep;5(9):1142-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In contrast, multicellular spheroids mimic heterogeneous cellular behavior and the consequent functional characteristics of in vivo solid tumors, and serve as important in vitro model to investigate tumor biology and responses to potential therapeutic agents.
  • In spheroids, the glucose consumption (2.1 p mole/cell/h) and lactate production (3.67 p mole/cell/h) was nearly 2-3 fold higher than in monolayer cells (0.83 and 1.43 p mole/cell/h respectively).
  • [MeSH-major] Deoxyglucose / pharmacology. Glioma / drug therapy. Glioma / radiotherapy. Radiation-Sensitizing Agents / pharmacology
  • [MeSH-minor] Animals. Apoptosis / drug effects. Apoptosis / radiation effects. Cell Cycle / drug effects. Cell Cycle / radiation effects. Cell Line, Tumor. Cell Proliferation / drug effects. Cell Proliferation / radiation effects. Chromosome Aberrations / drug effects. Chromosome Aberrations / radiation effects. Cytochromes c / metabolism. DNA Repair / drug effects. DNA Repair / radiation effects. Glucose / metabolism. Humans. Lactic Acid / biosynthesis. Mice. Proto-Oncogene Proteins c-bcl-2 / metabolism. Reactive Oxygen Species / metabolism. Spheroids, Cellular. bcl-2-Associated X Protein / metabolism

  • Genetic Alliance. consumer health - Glioma.
  • Hazardous Substances Data Bank. 2-DEOXY-D-GLUCOSE .
  • Hazardous Substances Data Bank. LACTIC ACID .
  • Hazardous Substances Data Bank. GLUCOSE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Biol Ther. 2006 Sep;5(9):1152-3 [16969124.001]
  • (PMID = 16855378.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Radiation-Sensitizing Agents; 0 / Reactive Oxygen Species; 0 / bcl-2-Associated X Protein; 33X04XA5AT / Lactic Acid; 9007-43-6 / Cytochromes c; 9G2MP84A8W / Deoxyglucose; IY9XDZ35W2 / Glucose
  •  go-up   go-down


85. Sebire NJ, Foskett M, Paradinas FJ, Fisher RA, Francis RJ, Short D, Newlands ES, Seckl MJ: Outcome of twin pregnancies with complete hydatidiform mole and healthy co-twin. Lancet; 2002 Jun 22;359(9324):2165-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of twin pregnancies with complete hydatidiform mole and healthy co-twin.
  • We assessed 77 twin pregnancies, comprising complete hydatidiform mole (CHM) and healthy co-twin, to ascertain the risks to the mother and baby of continuing the pregnancy, versus termination.
  • Chemotherapy to eliminate persistent gestational trophoblastic disease (pGTD) was required in three of 19 women (16%; 95% CI 3-39) who terminated their pregnancies in the first trimester, and in 12 of 58 (21%; 95% CI 11-33%) who continued their pregnancies.
  • [MeSH-major] Abortion, Spontaneous / etiology. Fetal Death / etiology. Hydatidiform Mole / complications. Pregnancy Complications, Neoplastic / physiopathology. Pregnancy Outcome. Twins. Uterine Neoplasms / complications


86. Kohorn EI, Kacinski BM, Stanley ER: Serum levels of macrophage colony-stimulating factor in trophoblastic disease. Gynecol Oncol; 2001 Mar;80(3):383-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: The aims of this study were to measure levels of colony stimulating factor (CSF-1) in patients with trophoblastic disease, to determine whether such measurement may be useful to supplement measurement of the prognostically reliable human chorionic gonadotrophin (hCG), and to assess whether measurement of CSF-1 may be helpful in predicting requirement for chemotherapy in patients with hydatidiform mole.
  • METHODS: Serial weekly serum samples were selected for CSF-1 assay from representative diagnostic groups of patients with trophoblastic disease: hydatidiform-mole with spontaneous resolution, low-risk post-hydatidiform-mole trophoblastic tumor, partial hydatidiform mole, high-risk metastatic gestational trophoblastic tumor, primary ovarian choriocarcinoma, and placental site trophoblastic tumor. hCG was measured by an in-house radioimmunoassay that measures all parts of the hCG molecule.
  • [MeSH-minor] Adolescent. Adult. Aged. Chorionic Gonadotropin / blood. Female. Humans. Hydatidiform Mole / blood. Hydatidiform Mole / drug therapy. Male. Middle Aged. Predictive Value of Tests. Pregnancy. Radioimmunoassay. Risk Factors

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Academic Press.
  • (PMID = 11263936.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA26504; United States / NCI NIH HHS / CA / CA32551; United States / PHS HHS / / P30-13330
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin; 81627-83-0 / Macrophage Colony-Stimulating Factor
  •  go-up   go-down


87. van der Knaap MS, Verhoeven NM, Maaswinkel-Mooij P, Pouwels PJ, Onkenhout W, Peeters EA, Stöckler-Ipsiroglu S, Jakobs C: Mental retardation and behavioral problems as presenting signs of a creatine synthesis defect. Ann Neurol; 2000 Apr;47(4):540-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They presented with developmental regression, extrapyramidal movement abnormalities, and intractable epilepsy, and they improved with treatment of creatine monohydrate.
  • Metabolic urine screening revealed elevations in all metabolites, expressed as millimoles per mole of creatinine, which suggests decreased creatinine excretion.
  • [MeSH-minor] Aspartic Acid / analogs & derivatives. Aspartic Acid / analysis. Body Fluids / chemistry. Brain Diseases, Metabolic / diagnosis. Brain Diseases, Metabolic / drug therapy. Brain Diseases, Metabolic / metabolism. Child, Preschool. Diagnosis, Differential. Epilepsy / diagnosis. Epilepsy / metabolism. Follow-Up Studies. Glycine / analogs & derivatives. Glycine / analysis. Humans. Infant. Magnetic Resonance Imaging. Magnetic Resonance Spectroscopy. Male

  • Genetic Alliance. consumer health - Mental Retardation.
  • MedlinePlus Health Information. consumer health - Child Mental Health.
  • MedlinePlus Health Information. consumer health - Mental Disorders.
  • Hazardous Substances Data Bank. GLYCINE .
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • Hazardous Substances Data Bank. CREATINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10762171.001).
  • [ISSN] 0364-5134
  • [Journal-full-title] Annals of neurology
  • [ISO-abbreviation] Ann. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 30KYC7MIAI / Aspartic Acid; 997-55-7 / N-acetylaspartate; GO52O1A04E / glycocyamine; MU72812GK0 / Creatine; TE7660XO1C / Glycine
  •  go-up   go-down


88. Smith ML, Shimomura E, Paul BD, Cone EJ, Darwin WD, Huestis MA: Urinary excretion of ecgonine and five other cocaine metabolites following controlled oral, intravenous, intranasal, and smoked administration of cocaine. J Anal Toxicol; 2010 Mar;34(2):57-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Urine EC concentrations peaked later than all other analytes and had longer detection times than the other minor metabolites.
  • With a 50 ng/mL cutoff concentration and following low doses of 10 to 45 mg cocaine by multiple routes, detection times extended up to 98 h.
  • Maximum concentrations (Cmax) were 6-14 mole % of those for benzoylecgonine, Cmax increased with dose, time to maximum concentration (Tmax) was independent of dose, and route of administration did not have a significant impact on Cmax or Tmax for metabolites.
  • EC is an analyte to consider for identifying cocaine use due to its stability in urine and long detection times.
  • [MeSH-minor] Adult. Biomarkers / metabolism. Biomarkers / urine. Gas Chromatography-Mass Spectrometry. Humans. Male. Substance Abuse Detection / methods

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. COCAINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Anal Toxicol. 2003 Oct;27(7):386-401 [14606991.001]
  • [Cites] J Anal Toxicol. 1995 May-Jun;19(3):133-8 [7564289.001]
  • [Cites] Biomed Chromatogr. 2005 Nov;19(9):677-88 [15841503.001]
  • [Cites] J Anal Toxicol. 2000 Oct;24(7):482-8 [11043650.001]
  • [Cites] J Anal Toxicol. 2007 Oct;31(8):462-8 [17988460.001]
  • [Cites] J Anal Toxicol. 2000 Oct;24(7):467-77 [11043648.001]
  • [Cites] Lancet. 2007 Mar 24;369(9566):1047-53 [17382831.001]
  • (PMID = 20223096.001).
  • [ISSN] 1945-2403
  • [Journal-full-title] Journal of analytical toxicology
  • [ISO-abbreviation] J Anal Toxicol
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / ZIA DA000414-13
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 129944-99-6 / 3-hydroxybenzoylecgonine; 5353I8I6YS / benzoylecgonine; DX2E9E17AV / ecgonine; I5Y540LHVR / Cocaine; J518R38LAU / benzoylnorecgonine; Y35FJB3QBJ / ecgonine methyl ester
  • [Other-IDs] NLM/ NIHMS317098; NLM/ PMC3159558
  •  go-up   go-down


89. Ak I, Ozalp S: Prognostic relevance of F-18 fluorodeoxyglucose positron emission tomography and computed tomography in molar pregnancy before evacuation. J Reprod Med; 2009 Jul;54(7):441-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic relevance of F-18 fluorodeoxyglucose positron emission tomography and computed tomography in molar pregnancy before evacuation.
  • OBJECTIVE: To assess prognostic significance of tumor metabolic activity of molar tissue by preevacuation F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) and computed tomography (CT) in patients clinically diagnosed with molar pregnancy.
  • After evacuation of molar tissue, histopathologic findings and clinical follow-up were used as reference standards for the study.
  • RESULTS: Six patients, 5 with complete and 1 with partial hydatidiform mole, had good outcome and normalization of beta-human chorionic gonadotropin (beta-hCG) levels within 5-7 weeks of evacuation.
  • These patients were treated with first-line single methotrexate or second-line etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine (EMA/CO) chemotherapy regimen.
  • Standardized uptake value of molar tissue within the uterus in patients with persistently/progressively elevated beta-hCG levels was significantly higher than that in patients whose serum beta-hCG levels normalized after evacuation of molar tissue.
  • [MeSH-major] Chorionic Gonadotropin, beta Subunit, Human / blood. Fluorodeoxyglucose F18. Hydatidiform Mole / radionuclide imaging. Positron-Emission Tomography / methods. Uterine Neoplasms / radionuclide imaging. Uterus / radionuclide imaging
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Female. Humans. Middle Aged. Pregnancy. Prognosis. Young Adult

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19691261.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Chorionic Gonadotropin, beta Subunit, Human; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


90. Dy Echo AV, Soriano-Estrella AS: Gestational trophoblastic tumor in pregnancy: a case report and review of the literature. Int J Gynecol Cancer; 2006 Mar-Apr;16(2):875-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • She had a history of hydatidiform mole for which curettage was done.
  • Due to worsening maternal pulmonary condition, the patient underwent primary, low segment cesarean section and was subsequently started on multidrug chemotherapy.
  • This case report emphasizes the importance of early diagnosis and treatment to improve the prognosis of both the mother and the infant.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gestational Trophoblastic Disease / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Chlorambucil / therapeutic use. Dactinomycin / therapeutic use. Female. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Methotrexate / therapeutic use. Pregnancy. Treatment Outcome

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681776.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 18D0SL7309 / Chlorambucil; 1CC1JFE158 / Dactinomycin; YL5FZ2Y5U1 / Methotrexate; MDC protocol
  •  go-up   go-down


91. Schoeberl MR: A model for the behavior of beta-hCG after evacuation of hydatidiform moles. Gynecol Oncol; 2007 Jun;105(3):776-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A model for the behavior of beta-hCG after evacuation of hydatidiform moles.
  • OBJECTIVES: The objective of this study is to develop a physical model of the behavior of beta-hCG following the complete evacuation of a hydatidiform mole.
  • Because hCG is an excellent marker for continued trophoblastic activity, the model can be used for early detection of persistent sites.
  • METHOD: The model was developed from analysis of the post surgical hCG decrease in a patient with Stage III gestational trophoblastic neoplasia.
  • In contrast to those studies, however, we assume that the decrease can be explained by the dilution of the residual hCG from two different tissue reservoirs, a tissue reservoir with a half-life of approximately 4 days and a reservoir with a longer half-life, in this case approximately 18 days.
  • RESULTS: Simple dilution of two tissue reservoirs explains behavior of hCG following tumor removal.
  • The model also explains the hCG decrease in a larger study of Japanese and Dutch women following the evacuation of uneventful hydatidiform moles.
  • CONCLUSIONS: Following an initial rapid drop in hCG after resolution of the mole, the patient should experience a slower drop associated with the dilution of residual hCG in the deep tissue reservoir.
  • The physical model suggests that even earlier detection of chemotherapy resistant persistent trophoblastic disease is possible if the patient's decrease in hCG is slower than a log-linear fit to the patient's previous data.
  • [MeSH-major] Chorionic Gonadotropin, beta Subunit, Human / metabolism. Hydatidiform Mole / metabolism. Models, Biological. Uterine Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17395254.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human
  •  go-up   go-down


92. Guldbakke KK, Khachemoune A, Deng A, Sina B: Naevus comedonicus: a spectrum of body involvement. Clin Exp Dermatol; 2007 Sep;32(5):488-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Naevus comedonicus: a spectrum of body involvement.
  • Naevus comedonicus (NC) is a rare developmental anomaly, with < 200 cases reported in the literature.
  • We review the current literature, emphasizing the clinical features, associated conditions and therapeutic options.
  • [MeSH-major] Nevus / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Anti-Bacterial Agents / therapeutic use. Anti-Inflammatory Agents / therapeutic use. Dermabrasion / methods. Dermatologic Agents / therapeutic use. Female. Humans. Male. Rare Diseases / drug therapy. Rare Diseases / pathology. Rare Diseases / surgery

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Moles.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17509056.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Inflammatory Agents; 0 / Dermatologic Agents
  • [Number-of-references] 34
  •  go-up   go-down


93. Piura B, Shaco-Levy R: [Placental site trophoblastic tumor]. Harefuah; 2007 Jan;146(1):62-7, 77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since PSTT is less sensitive to chemotherapy than GTDs originating from cytotrophoblast and syncytiotrophoblast (hydatidiform mole, invasive mole, and choriocarcinoma), hysterectomy is the mainstay of treatment.
  • Systemic multi-agent chemotherapy is administered in the presence of disease extension beyond the uterus and considered in the presence of other adverse prognostic factors.
  • The EP/EMA regimen seems to be the most effective chemotherapy available to date for PSTT.
  • Although PSTT produces less human chorionic gonadotropin (hCG) than choriocarcinoma, beta-hCG is still the best available serum marker for monitoring the response to treatment and for follow-up.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17294852.001).
  • [ISSN] 0017-7768
  • [Journal-full-title] Harefuah
  • [ISO-abbreviation] Harefuah
  • [Language] heb
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Israel
  • [Number-of-references] 20
  •  go-up   go-down


94. Deng L, Yan X, Zhang J, Wu T: Combination chemotherapy for high-risk gestational trophoblastic tumour. Cochrane Database Syst Rev; 2009;(2):CD005196
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy for high-risk gestational trophoblastic tumour.
  • BACKGROUND: Gestational trophoblastic disease (GTD) includes gestational trophoblastic tumour and hydatidiform mole.
  • A number of chemotherapy regimens are used for treating the disease, such as methotrexate, actinomycin D and cyclophosphamide (MAC), methotrexate, actinomycin D, cyclophosphamide, doxorubicin, melphalan, hydroxyurea and vincristine (CHAMOC), etoposide, methotrexate and actinomycin (EMA) plus cyclophosphamide and vincristine (CO) (EMA-CO), etoposide, methotrexate and actinomycin (EMA) plus etoposide and cisplatin(EP) (EMA-EP).
  • The efficacy of these drugs has not been systematically reviewed.
  • OBJECTIVES: To determine the efficacy and safety of combination chemotherapy in treating high-risk GTT.
  • SELECTION CRITERIA: The review included randomised controlled trials (RCTs) or quasi-RCTs of combination chemotherapy for treating high-risk GTT.
  • Patients with placental-site trophoblastic tumour (PSTT), who had received chemotherapy in the previous two weeks, or patients with chemotherapy intolerance were excluded.
  • AUTHORS' CONCLUSIONS: The methodological limitations of the included study prevent any firm conclusions about the best combination chemotherapy regimen for high-risk GTT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gestational Trophoblastic Disease / drug therapy
  • [MeSH-minor] Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Hydatidiform Mole / drug therapy. Hydroxyurea / administration & dosage. Melphalan / administration & dosage. Methotrexate / administration & dosage. Pregnancy. Trophoblastic Tumor, Placental Site / drug therapy. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2013;1:CD005196 [23440800.001]
  • [UpdateOf] Cochrane Database Syst Rev. 2006;(3):CD005196 [16856085.001]
  • (PMID = 19370618.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q41OR9510P / Melphalan; X6Q56QN5QC / Hydroxyurea; YL5FZ2Y5U1 / Methotrexate; MAC combination
  • [Number-of-references] 42
  •  go-up   go-down


95. Smith CJ, Perfetti TA, Morton MJ, Rodgman A, Garg R, Selassie CD, Hansch C: The relative toxicity of substituted phenols reported in cigarette mainstream smoke. Toxicol Sci; 2002 Sep;69(1):265-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the human exposure situation, the toxicity of MS phenols is a complex interaction, with contributions made by the following factors: toxicity per mole; MS concentration; synergistic, additive or antagonistic interactions with other MS components; host susceptibility; metabolism; and individual smoking behavior and inhalation patterns.
  • Studies of this type can play an important role in identifying MS components for reduction or removal.
  • [MeSH-minor] Animals. Cell Survival / drug effects. Chemistry, Physical. Electrochemistry. Free Radicals / chemistry. Half-Life. Leukemia L1210 / drug therapy. Leukemia L1210 / pathology. Physicochemical Phenomena. Quantitative Structure-Activity Relationship. Solubility. Tissue Distribution

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12215682.001).
  • [ISSN] 1096-6080
  • [Journal-full-title] Toxicological sciences : an official journal of the Society of Toxicology
  • [ISO-abbreviation] Toxicol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Free Radicals; 0 / Phenols; 0 / Smoke
  •  go-up   go-down


96. Therasakvichya S: Gestational trophoblastic disease in 2005. J Med Assoc Thai; 2005 Oct;88 Suppl 2:S119-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Approximately 20% of patients will develop malignant sequelae requiring administration of chemotherapy after evacuation of hydatidiform moles.
  • Most patients with postmolar gestational trophoblastic disease will have non-metastatic molar proliferation or invasive moles, but gestational choriocarcinomas and metastatic disease can develop in this setting.
  • Although much rarer than hydatidiform moles or gestational choriocarcinomas, placental site trophoblastic tumors can develop after any type of pregnancy.
  • [MeSH-major] Gestational Trophoblastic Disease / pathology. Gestational Trophoblastic Disease / therapy. Pregnancy Complications, Neoplastic / pathology. Pregnancy Complications, Neoplastic / therapy
  • [MeSH-minor] Female. Humans. Neoplasm Metastasis. Neoplasm Staging. Pregnancy

  • Genetic Alliance. consumer health - Gestational Trophoblastic Disease.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17722325.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Thailand
  • [Number-of-references] 22
  •  go-up   go-down


97. Feng HC, Tsao SW, Ngan HY, Xue WC, Kwan HS, Siu MK, Liao XY, Wong E, Cheung AN: Overexpression of prostate stem cell antigen is associated with gestational trophoblastic neoplasia. Histopathology; 2008 Jan;52(2):167-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: Hydatidiform mole (HM) is the most common type of gestational trophoblastic disease.
  • A proportion of patients with HM develop gestational trophoblastic neoplasia (GTN) requiring chemotherapy.
  • METHODS AND RESULTS: Using cDNA microarray, differential expression of prostate stem cell antigen (PSCA) was identified in HMs that developed GTN compared with those that spontaneously regressed.
  • Significant overexpression of PSCA RNA (P = 0.037) and protein (P < 0.05) in aggressive HM was verified by real-time polymerase chain reaction (PCR) and immunohistochemical analysis in 10 first-trimester placentas, 36 HM that subsequently regressed and 11 HM that developed GTN.
  • [MeSH-major] Gestational Trophoblastic Disease / metabolism. Hydatidiform Mole / metabolism. Membrane Glycoproteins / metabolism. Neoplasm Proteins / metabolism. Prostatic Neoplasms / metabolism
  • [MeSH-minor] Adolescent. Adult. Antigens, Neoplasm. Biomarkers, Tumor / metabolism. Cell Proliferation. DNA, Neoplasm / genetics. Female. GPI-Linked Proteins. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Pregnancy. Signal Transduction / genetics. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18184265.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins; 0 / PSCA protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


98. Jauniaux E, Maymon R, Greenwold N, Hustin J, Moroz C: Diminished expression of placental isoferritin p43 component in first trimester abnormal pregnancies. Placenta; 2000 May;21(4):408-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human placental isoferritin (PLF) is a sub-type of human ferritin mainly composed of a 43 kD protein, which has an immunosuppressive activity and may be involved in the downregulation of the maternal immune system during pregnancy.
  • The aim of this study was to evaluate the distribution of p43 in the placental tissue of abnormal first trimester pregnancies.
  • Samples of villous and decidual tissues were collected between 7 and 12 weeks' gestation from 28 missed abortions and eight complete moles.
  • Samples of placental tissue from 20 normal pregnancies of similar gestational age were used as controls.
  • Compared to controls, specific p43 immunoreactivity was low in the villous syncytiotrophoblast of missed abortions and absent from all villous cellular types in complete moles.
  • [MeSH-major] Abortion, Missed / metabolism. Cytokines / metabolism. Ferritins / metabolism. Hydatidiform Mole / metabolism. Placenta / metabolism. Pregnancy Complications, Neoplastic. Uterine Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Harcourt Publishers Ltd.
  • (PMID = 10833377.001).
  • [ISSN] 0143-4004
  • [Journal-full-title] Placenta
  • [ISO-abbreviation] Placenta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Cytokines; 9007-73-2 / Ferritins
  •  go-up   go-down


99. Wang YX, Zhang X, Guan YL, Jang AY, Long ZQ: [Assessment of staging and prognostic scoring system for malignant trophoblastic neoplasia]. Zhonghua Fu Chan Ke Za Zhi; 2005 Feb;40(2):87-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Through assessing the high-risk factors except clinical stages for 223 patients before treatment according to International Federation of Gynecology and Obstetrics (FIGO) scoring system published in 2000, appropriate treatments were selected for the different patients.
  • RESULTS: Forty-three of 78 cases of choriocarcinomas were with high-risk factors, the other 35 cases were with low-risk factors; 7 of 145 cases of invasive moles were with high-risk factors and the others were with low-risk factors.
  • The primary chemotherapy principle was that one agent was used for those patients with low-risk factors and two or multiple-agents were used for those patients with high-risk factors.
  • No patient died of drug toxicity or complication.
  • CONCLUSION: Selection of treatment approaches according to the prognostic assessment of malignant trophoblastic neoplasia could lead to promising survival rate with no uncurable complication and toxic effects.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Trophoblastic Neoplasms / drug therapy. Trophoblastic Neoplasms / pathology. Uterine Neoplasms / drug therapy. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Choriocarcinoma / drug therapy. Choriocarcinoma / mortality. Choriocarcinoma / pathology. Chorionic Gonadotropin / blood. Dactinomycin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Hydatidiform Mole, Invasive / drug therapy. Hydatidiform Mole, Invasive / mortality. Hydatidiform Mole, Invasive / pathology. Methotrexate / administration & dosage. Neoplasm Staging / methods. Neoplasm Staging / standards. Pregnancy. Prognosis. Severity of Illness Index. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15840285.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin; 1CC1JFE158 / Dactinomycin; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


100. Lloyd-Jones GC, Alder RW, Owen-Smith GJ: Intermolecular insertion of an N,N-heterocyclic carbene into a nonacidic C-H bond: Kinetics, mechanism and catalysis by (K-HMDS)2 (HMDS = Hexamethyldisilazide). Chemistry; 2006 Jul 5;12(20):5361-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, the rate can be satisfactorily predicted by a mole-fraction-weighted net rate constant: -d[2]/dt = ({x2 k(uncat)} + {(1-x2) k(cat)})[2]1[toluene]1, in which x2 is determined by a standard bimolecular complexation equilibrium term.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16673429.001).
  • [ISSN] 0947-6539
  • [Journal-full-title] Chemistry (Weinheim an der Bergstrasse, Germany)
  • [ISO-abbreviation] Chemistry
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down






Advertisement